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The FYN-TRAF3IP2 gene fusion drives 
oncogenic NF-κB signaling in peripheral T cell lymphoma 
 
Christine S. Kim 
 
 
Angioimmunoblastic T cell lymphoma (AITL) and peripheral T cell lymphoma not-otherwise-
specified (PTCL, NOS) have poor prognosis and lack actionable targets for directed therapies in 
most cases. Here we report the identification of FYN-TRAF3IP2 as a novel highly recurrent 
oncogenic gene fusion in AITL and PTCL, NOS tumors. Mechanistically, FYN-TRAF3IP2 triggers 
aberrant NF-κB activity by engaging TRAF6 downstream of T cell receptor signaling. Moreover, 
FYN-TRAF3IP2 expression in hematopoietic progenitors induces NF-κB-driven T cell 
transformation in mice and cooperates with loss of the Tet2 tumor suppressor in PTCL 
development. Therapeutically, abrogation of NF-κB signaling in FYN-TRAF3IP2-induced tumors 
via IκB kinase inhibitors delivers strong anti-lymphoma effects in vitro and in vivo. These results 
formally demonstrate an oncogenic role for FYN-TRAF3IP2 and NF-κB signaling in the 
pathogenesis of PTCL.
 i 
Table of Contents 
 
List of Figures ………………………………………………………………………………… ii 
List of Tables………………………………………………………………………....……….. iii 
Acknowledgements …………………………………………………………………………… iv 
Dedication ……………………………………………………………………...………………. v 
  
Chapter 1: Introduction ……………………………………………………………………… 1 
I. Peripheral T cell lymphoma ……………………………………….……………………….. 1 
History ………………………………………………………………………………………... 1 
Clinical presentation and diagnosis ……………………………………………………….. 3 
Epidemiology ………………………………………………………………………………… 4 
Genetic and molecular landscape of PTCL ………………………………………………. 5 
Angioimmunoblastic T cell lymphoma ……………………….…………………... 6 
Anaplastic large cell lymphoma ………………………………………………..…. 10 
Extranodal NK/T cell lymphoma, nasal type …………………………………….. 11 
Peripheral T cell lymphoma, not otherwise specified …………………………… 11 
Treatment options and outcome …………………………………………………………… 14 
FDA-approved agents in relapsed and refractory peripheral T cell lymphomas  16 
Incorporating novel agents into CHOP regimen………………………………… 17 
Targeted therapy in peripheral T cell lymphomas ………………………………. 18 
II. NF-κB signaling in lymphoma ……………………………………………………………… 22 
Overview of NF-κB signaling pathway …………………………………………………….. 22 
Components of the NF-κB System ……………………….……………………… 22 
The canonical pathway …………………………………………………………… 25 
The alternative pathway ………………………………………………………….. 27 
Physiologic role of NF-κB signaling in normal lymphoid tissue ………………………… 28 
Pathogenic activation of NF-κB in lymphoid neoplasms ………………………………… 29 
Diffuse large B cell lymphoma ……………...…………………………………….. 30 
Hodgkin lymphoma ………………………………………………………………... 31 
MALT lymphoma …………………………………………………………………... 32 
Multiple myeloma ………………………………………………………………….. 33 
Peripheral T cell lymphoma ………………………………………………………. 34 
Therapeutic targeting of NF-κB …………………………………………………………….. 35 
III. Fyn Src family kinase ………………………………………………………………………. 37 
Domain structure of Fyn kinase ……………………………………………………………. 37 
Regulation of Fyn activation ………………………………………………………………... 39 
The role of Fyn in T cell development and function ……………………………………… 40 
IV. NF-κB activating signal transducer, TRAF3IP2 ………………………………………… 41 
V. Specific Aims ………………………………………………………………………………... 44 
  
Chapter 2: Identification of a FYN-TRAF3IP2 gene fusion in PTCL ………………….. 45 
Chapter 3: Functional characterization of FYN-TRAF3IP2 ……………………………. 50 
Chapter 4: Oncogenic role of FYN-TRAF3IP2 in PTCL ………………………………… 57 
Chapter 5: NF-κB activation as driver and therapeutic target in FYN-TRAF3IP2 
induced PTCL ………………………………………………………………………………… 64 
  
Conclusions …………………………………………………………………………………... 69 
  
Materials and Methods ………………………………………………………………………... 72 
References ……………………………………………………………………………………... 85 
  
 ii 
List of Figures 
 
Chapter 1  
Figure 1.1 – Co-occurrence of frequent mutations in AITL …………………………….. 7 
Figure 1.2 – Genes constituting T cell receptor activation pathway are recurrently 
altered in AITL. …………………………………………………………………………... 9 
Figure 1.3 – Treatment algorithm for initial presentation of peripheral T- cell 
lymphoma ………………………………………………………………………………… 15 
Figure 1.4 – Overall survival of patients with the common subtypes of peripheral T 
cell lymphoma …………………………………………………………………………… 16 
Figure 1.5 – Treatment algorithm for relapsed/refractory peripheral T- cell lymphoma 20 
Figure 1.6 – Components of the NF-κB System ………………………………………… 23 
Figure 1.7 – Canonical and alternative pathway of NF-κB activation …………………. 25 
Figure 1.8 – Fyn and Lck, Src family kinases ……………………………………………. 38 
Figure 1.9 – Domain structure of TRAF3IP2 …………………………………………….. 42 
Figure 1.10 – Activation of IL-17 Signal Transduction ………………………………….. 42 
  
Chapter 2  
Figure 2.1 – Identification of the FYN-TRAF3IP2 gene fusion in PTCL. ……………… 46 
Figure 2.2 – FYN-TRAF3IP2 detection by RT-PCR and dideoxynucleotide 
sequencing. ……………………………………………………………………………… 48 
  
Chapter 3  
Figure 3.1 – T cells do not functionally express IL17 receptors. ………………………. 50 
Figure 3.2 – FYN-TRAF3IP2 drives NF-κB activation in response to TCR-induced 
PKC signaling. …………………………………………………………………………… 51 
Figure 3.3 – Membrane localization of FYN-TRAF3IP2. ……………………………….. 53 
Figure 3.4 – Knock out and reconstitution of CARD11 in Jurkat cells. ……………….. 54 
Figure 3.5 – FYN-TRAF3IP2 engages TRAF6 to activate CARD11-independent NF-
κB signaling. ……………………………………………………………………………... 55 
Figure 3.6 – Schematic representation FYN-TRAF3IP2 signaling in T cells………….. 56 
  
Chapter 4  
Figure 4.1 – Schematic representation of bone marrow transplant experiment 
analyzing the lymphomagenic activity of FYN-TRAF3IP2. …………………………. 58 
Figure 4.2 – Expression of FYN-TRAF3IP2 in mouse hematopoietic progenitors 
induces PTCL, NOS. ……………………………………………………………………. 59 
Figure 4.3 – FYN-TRAF3IP2-induced lymphomas infiltrate lymphoid organs, bone 
marrow and solid tissues in mice. ……………………………………………………... 61 
Figure 4.4 – FYN-TRAF3IP2-induced mouse lymphoma T cells show limited TFH 
features. ………………………………………………………………………………….. 62 
Figure 4.5 – FYN-TRAF3IP2-induced mouse PTCL, NOS are transplantable. ……… 63 
  
Chapter 5  
Figure 5.1 – NF-κB activation in FYN-TRAF3IP2-induced mouse PTCL, NOS. …….. 65 
Figure 5.2 – Transcriptomic profiling of FYN-TRAF3IP2 mouse PTCL, NOS by 
RNAseq. ………………………………………………………………………………….. 66 
Figure 5.3 – Anti-lymphoma effects of NF-κB inhibition in FYN-TRAF3IP2-induced 





List of Tables 
 
Chapter 1  
Table 1.1 – List of mature T and NK cell neoplasm entities based on the 2016 WHO 
classification ……………………………………….…………………………………….. 2 
Table 1.2 – Common chromosomal and molecular abnormalities in peripheral T cell 
lymphoma. ……………………………………………………………………………….. 13 
Table 1.3 – Novel agents approved for relapsed/refractory peripheral T cell 
lymphomas ………………….…………………………………………………………… 17 
Table 1.4 – Key ongoing and recently completed phase III trials ……………………… 18 
Table 1.5 – Single-agent therapies under investigation for relapsed/ refractory 
peripheral T cell lymphomas …………………………………………………………… 21 
Table 1.6 – Selected list of published Fyn and Lck interacting partners ……………… 39 
  
Chapter 2  
Table 2.1 – Chimeric FYN-TRAF3IP2 RNAseq reads. …………………………………. 45 
Table 2.2 – List of patient samples analyzed by reverse transcription and PCR 
amplification. …………………………………………………………………………….. 47 
Table 2.3 – Genomic breakpoint of FYN-TRAF3IP2 fusion analyzed by whole 
genome sequencing. ……………………………………………………………………. 49 
Table 2.4 – Mutational profile of FYN-TRAF3IP2 harboring sample analyzed by 
whole genome sequencing. ……………………………………………………………. 49 
  
Chapter 4  






The past four years have been truly special in many ways. I would not have been where I am today 
without the support and guidance of so many people. 
 
First and foremost, I have been extremely fortunate to have Dr. Adolfo Ferrando as my thesis 
advisor and a mentor. Thank you for providing a wonderful learning environment, thank you for 
your dedicated mentorship and undying enthusiasm for science, thank you for pushing me to think 
bigger and be bolder, and above all, thank you for believing in me even when I had self-doubts. 
 
I am incredibly grateful to Dr. Teresa Palomero for her thoughtful guidance and encouragement 
when I needed them the most. Thank you for your invaluable insights as I navigated the world of 
peripheral T cell lymphoma and the path to become a better scientist, as well as in wedding 
planning, marriage, and motherhood. 
 
Thank you to my thesis committee Dr. Laura Pasqualucci, Dr. Shan Zha, and Dr. Swarnali Acharyya 
for their continued support and inputs over the years as well as Dr. Riccardo Dalla-Favera for 
participating in my thesis defense. 
 
I have to thank the members of the Ferrando lab, both past and present. I cannot imagine a better 
group of people to learn from and work with. My graduate work would not have been possible 
without their expertise, collegiality and patience. Thank you so much for your technical support, 
scientific discussions, and most importantly, kind friendship. You made lab life enjoyable with silly 
jokes, passionate (but sometimes very weird) takes on food, and late-night laughs. 
 
Thank you to MD/PhD and CMBS program leadership for their commitment to students. I sincerely 
appreciate all the opportunities provided through this program. I’d be remiss if I did not thank the 
enormous amount of administrative support, in particular Zaia Sivo, Jeffrey Brandt, Kate Matthews, 
and Becky Spurr. 
 
Lastly, I would never have achieved any of this without the love and support from my family and 
friends. I especially would like to thank the incredible group of women who have shaped me over 
the past thirty years. Thank you, Mom, for your dedication and strength. I love you and I am so 
proud to be your daughter. Thank you, Grandmother, for raising me with all the care and kindness 
in the world. Spending winter nights watching TV with you on the ‘ondol (heated stone)’ floor is one 
of my dearest childhood memories. I wish I could see you more often. To my little sister, Nakyung, 
thank you for being the best sister anyone can ever ask for. I am blessed to have someone who 
understands me so well. And Parker. Every day, you make me a better version of myself. 
Thank you, friends. There are too many of you to name individually, but I don’t know what I have 
done to be so lucky to have you all in my life. And thank you James, my best friend, for your endless 





To Parker Jinyoung Moon. 
My dearest, 
You turned my world upside down, 
And my heart cannot be any fuller. 
 
I love you. 
 1 
Chapter 1: Introduction 
 
I. Peripheral T cell lymphoma 
 
History 
T cell lymphomas were first recognized as distinct entities from B cell non-Hodgkin lymphomas 
(NHLs) in 1974, when Robert Lukes and Robert Collins proposed the Lukes-Collins classification 
of lymphomas (Lukes and Collins 1974). By 1988, the Kiel classification, a system widely used in 
Europe and Asia developed by Karl Lennert, was also updated to place lymphomas under separate 
columns of B cell and T cell types (Feller and Diebold 2004). The specific diagnoses of mature T 
cell lymphomas became widely accepted with the introduction of the REAL (revised European-
American Classification of Lymphoid Neoplasms) classification in 1994 (Harris et al. 1994). The 
first system of an international consensus, the REAL classification listed over 10 disease entities 
as “Peripheral T cell and NK-cell neoplasms.” 
In 2001, the World Health Organization (WHO) largely adopted the REAL system to develop an 
internationally authoritative hematologic malignancy classification system and categorized 14 
entities of clonal mature T- and NK-cell tumors as one group mostly based on the clinical 
presentation and histological morphology (Jaffe et al. 2001). The WHO has since updated the 
system to incorporate the new information uncovered in T cell lymphoma research. The most recent 
WHO system of 2016 catalogues over 25 discrete diagnoses under the heading of “mature T- and 
NK-cell neoplasms” (Table 1.1), which include both cutaneous T cell lymphoma (CTCL) and 
peripheral T cell lymphoma (PTCL), reflecting the remarkable heterogeneity of this group of disease 
that was further elucidated by the molecular advances in the understanding of the tumor 
pathobiology (Swerdlow et al. 2016).  
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Table 1.1 – List of mature T and NK cell neoplasm entities based on the 2016 WHO classification 
 




T cell prolymphocytic leukemia Definite 
T cell large granular lymphocytic leukemia Definite 
Chronic lymphoproliferative disorder of NK cells Provisional 
Aggressive NK cell leukemia Definite 
Systemic EBV+ T cell lymphoma of childhood Definite 
Hydroa vacciniforme-like lymphoproliferative disorder Definite 
Adult T cell leukemia/lymphoma Definite 
Predominantly 
nodal diseases 
Peripheral T cell lymphoma, Not otherwise specified Definite 
Angioimmunoblastic T cell lymphoma Definite 
Follicular T cell lymphoma Provisional 
Nodal peripheral T cell lymphoma with TFH phenotype Provisional 
Anaplastic large-cell lymphoma, ALK+ Definite 
Anaplastic large-cell lymphoma, ALK- Definite 




Extranodal NK-/T cell lymphoma, nasal type Definite 
Enteropathy-associated T cell lymphoma  Definite 
Monomorphic epitheliotropic intestinal T cell lymphoma  Definite 
Indolent T cell lymphoproliferative disorder of the GI tract Provisional 
Hepatosplenic T cell lymphoma Definite 




Mycosis fungoides  Definite 
Sézary syndrome Definite 
Primary cutaneous CD30+ T cell lymphoproliferative disorders 
- Lymphomatoid papulosis 
- Primary cutaneous anaplastic large cell lymphoma 
Definite 
Primary cutaneous γδ T cell lymphoma Definite 
Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T cell 
lymphoma 
Provisional 
Primary cutaneous acral CD8+ T cell lymphoma Provisional 





Clinical presentation and diagnosis 
A diverse array of different T cell neoplasms comprises T cell lymphoma (TCL), potentially related 
to the heterogeneity of its normal mature T cell counterparts. Even with the 27 distinct entities 
currently defined by the WHO diagnostic standard (Table 1.1), about a third of TCL cases still do 
not meet the existing criteria for any classification and receive a diagnosis of exclusion, PTCL, not 
otherwise specified (PTCL, NOS). 
WHO diagnostic criterion for each entity involve clinical, phenotypic, and morphological feature of 
the disease. TCL can be broadly grouped into two categories based on the clinical presentation: 
cutaneous T cell lymphoma (CTCL) with predominantly cutaneous presentation and peripheral T 
cell lymphoma (PTCL), which encompasses leukemic (disseminated), nodal, and extranodal 
diseases (Table 1.1) (Campo et al. 2008). Leukemic diseases, like T-prolymphocytic leukemia (T-
PLL) and adult T cell leukemia-lymphoma (ATL or ATLL), are characterized by circulating malignant 
T lymphoid cells that lead to marked lymphocytosis, generalized lymphadenopathy, and 
hepatosplenomegaly. Nodal PTCLs include some of the better described entities, such as 
angioimmunoblastic T cell lymphoma (AITL) and anaplastic large cell lymphoma (ALCL). Similar to 
other aggressive lymphomas, they commonly present with generalized lymphadenopathy and 
systemic B symptoms and, despite what the name suggests, often involve extranodal disease. On 
the other hand, extranodal lymphoma frequently is a localized disease without any nodal 
involvement. They are defined by the localization of the tumor: extranodal NK/T cell lymphoma, 
nasal type (ENKTCL), subcutaneous panniculitis-like T cell lymphoma (SPTCL), enteropathy 
associated T cell lymphoma (EATL), and hepatosplenic T cell lymphoma (HSTCL). Lastly, 
cutaneous T cell lymphomas (CTCLs), the most prominent of which are Sézary syndrome (SS) and 
mycosis fungoides (MF), present with various manifestations on the skin, which range from plaques 
to erythema. Lastly, PTCL, NOS, an inherently heterogeneous subgroup, most often presents in 
the lymph nodes, but can also be extranodal. 
Differential diagnosis of PTCL heavily relies on histopathology of the disease. With the exception 
of Anaplastic Lymphoma Kinase (ALK)-translocated ALCL (ALK+), the only PTCL entity to date 
defined by a genetic marker, morphologic characteristics represent the hallmark features of each 
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PTCL subgroup. AITL consists of polymorphous infiltrate involving lymph nodes with a prominent 
proliferation of high endothelial venules and follicular dendritic cells (Swerdlow et al. 2017). ALCL 
is composed of large cells with round or pleomorphic, often horseshoe-shaped nuclei with multiple 
prominent nucleoli.  Follicular T cell lymphoma (FTCL) demonstrates a nodular growth pattern in 
lymph nodes. 
Increasing number of studies reveal that each PTCL subtype is a clinically distinct disease that, for 
efficient treatment, warrants therapeutic strategy uniquely tailored to its underlying pathogenesis. 
Therefore, diagnostic precision of PTCL has become more important than ever. However, arriving 
at a confident diagnosis remains difficult. The diagnostic workup varies widely among institutions 
(I et al. 2017), and pathologists often disagree on the diagnosis of a specific subtype (Vose et al. 
2008, Weisenburger et al. 2011a). The overall rarity and heterogeneity of this disease, the complex 
diagnostic criteria that necessitates exhaustive amounts of testing and expertise, and the lingering 
ambiguity in boundaries between some entities due to incomplete understanding of the underlying 
biology all contribute to the challenges of diagnosing and effectively treating these cancers.  
Epidemiology 
PTCL incidence varies substantially across geographical regions, accounting for 10 to 15% of NHL 
in Western countries and 20 to 25% in Asia (1997, Anderson et al. 1998, Vose et al. 2008). The 
PTCL incidence is higher in Asia, Africa, and the Caribbean possibly due to the frequency of 
endemic Human T-lymphotropic virus 1 (HTLV-1) and Epstein-Barr Virus (EBV) infections, which 
are associated with ATL and NKTCL respectively (Arber et al. 1993, Jaffe et al. 1996, Au et al. 
2009, Laurini et al. 2012, Chihara et al. 2014, Adams et al. 2016). In the United States, the age-
adjusted incidence rate for PTCL more than quadrupled from 0.2 to 0.9 cases per 100,000 
population from 1992 to 2005 (Abouyabis et al. 2008). The surge in incidence rate is partially 
explained by the increased awareness of the previously under-diagnosed lymphoma subtypes 
since the introduction of the WHO classification system. Most PTCL subtypes are more frequent in 
males, and the incidence increases with age (Abouyabis et al. 2008, Vose et al. 2008, Adams et 
al. 2016). 
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The two most common subtypes are PTCL, NOS (25.9%) and AITL (18.5%) (Vose et al. 2008). 
Reflecting the challenge of subtyping PTCLs under current diagnostic schemes, about 30% of T 
cell lymphomas in North America and Europe do not meet the criteria for a distinct diagnosis and 
are classified as PTCL, NOS (Vose et al. 2008, Weisenburger et al. 2011b). The most common 
discrete PTCL entity, AITL is more frequent in Europe (28.7%) than in North America (16.0%) (Vose 
et al. 2008, Federico et al. 2013). Both PTCL, NOS and AITL primarily affect the elderly with a 
median age at diagnosis of 60 years for PTCL, NOS (Weisenburger et al. 2011b) and 65 years for 
AITL (Federico et al. 2013). While the neoplastic T cells of PTCL, NOS and AITL are not associated 
with viral infections, studies of their disease biopsies have found that EBV-infected bystander B 
cells are present in about 50% of the cases (Tan et al. 2006). Other more common PTCL subtypes 
include ENKTCL (10.4%), ATLL (9.6%), ALK-positive ALCL (6.6%), and ALK-negative ALCL 
(5.5%) (Vose et al. 2008). 
Genetic and molecular landscape of PTCL 
Molecular studies of PTCL have demonstrated the potential for a more accurate classification and 
a more efficient subtype-specific targeted therapy. Early on, gene expression profiling studies have 
identified distinct signatures enriched in major PTCL entities such as AITL. The gene expression 
signature of AITL resembles that of follicular T-helper (TFH) cells, a subset of CD4+ T helper cells 
residing in the germinal centers, establishing TFH cells as the normal counterpart of the AITL tumor 
(de Leval et al. 2007). Notably, AITL-associated transcriptional signatures were present in about 
15% of tumors diagnosed as PTCL, NOS, supporting that molecular characterization may deliver 
a more accurate PTCL classification than histology (Iqbal et al. 2014). 
Advances in genomic sequencing technologies have permitted identification of recurrent genetic 
alterations in nearly every PTCL subtype albeit stopping short of uncovering entity-defining genetic 
markers. Across various subtypes, exome sequencing studies have revealed point mutations, 
indels, and copy number changes in genes involved in epigenetic regulation, T cell receptor (TCR) 
and co-stimulatory signaling, and JAK/STAT pathway (Table 1.2). In addition, a number of 
recurrent fusion oncogenes have emerged in PTCL, adding to the NPM-ALK gene fusion 
characteristic of ALK+ ALCL first identified in 1994 (Morris et al. 1994). Considering the important 
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role that chromosomal rearrangements play in the pathogenesis and clinical management of other 
hematologic malignancies (Das and Tan 2013, Wang et al. 2017), identification of fusion 
oncogenes in PTCL may help us better understand the disease and facilitate improved therapy in 
clinical settings. 
The sections below discuss our current insight into the genetic and molecular landscape of some 
of the more common PTCLs.  
Angioimmunoblastic T cell lymphoma 
Following the gene expression profiling study that revealed TFH cells as the potential normal 
counterpart of AITL (de Leval et al. 2007), mutational analyses have uncovered highly recurrent 
somatic mutations in AITL with roles in TFH transformation. Genes most often altered in AITL 
include those involved in epigenetic regulation, T cell receptor (TCR) activation, and RHOA 
signaling (Table 1.2). 
RhoA GTPase, encoded by the RHOA gene, is a molecular switch that regulates multiple biological 
processes, best characterized for its role in cytoskeleton remodeling. Studies in T cells have 
reported its role in polarization, migration and TCR signaling (del Pozo et al. 1999, Corre et al. 
2001, Heasman et al. 2010, Mou et al. 2012). Heterozygous missense mutations of RHOA are 
present in up to 70% of AITL (Figure 1.1a), highlighting the central role of RHOA in the 
pathogenesis of AITL (Manso et al. 2014, Palomero et al. 2014, Sakata-Yanagimoto et al. 2014, 
Yoo et al. 2014, Wang et al. 2015, Ondrejka et al. 2016). RHOA G17V allele, which accounts for 
over 90% of these RHOA mutations, functions as an inactive and dominant negative form, likely 
blocking the activity of wild type RHOA (Palomero et al. 2014, Sakata-Yanagimoto et al. 2014, Yoo 
et al. 2014). Importantly, RHOA G17V expression in mouse CD4+ T cells significantly increases 
differentiation towards the TFH lineage and eventually induces T cell lymphoma that faithfully 
recapitulate the characteristics of human AITL in cooperation with TET2 loss (Cortes et al. 2018). 
Mutations in epigenetic modulators, such as TET2, DNMT3A and IDH2, are widely present in 
hematological malignancies. TET2 inactivating mutations are especially prevalent in AITL (70%) 
(Figure 1.1a) (Palomero et al. 2014, Sakata-Yanagimoto et al. 2014) and are associated with 
expression of TFH markers, advanced stage disease, and adverse clinical outcome (Lemonnier et 
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al. 2012). Notably, mice studies have demonstrated that loss of Tet2 results in increased self-
renewal and repopulating ability of hematopoietic stem cells (Ko et al. 2011, Ko and Rao 2011, Koh 
et al. 2011, Li et al. 2011, Moran-Crusio et al. 2011, Quivoron et al. 2011, Kunimoto et al. 2012, 
Shide et al. 2012). 
IDH2 mutations in PTCL occur exclusively in AITL (20-45%) and involve only the position R172 
(Figure 1.1a) (Cairns et al. 2012, Wang et al. 2015). R172 mutations in IDH2 lead to accumulation 
of the I-enantiomer of 2-hydroxyglutarate, which antagonizes the activity of the TET family of 
enzymes, and reportedly cooperate with the TET2 inactivation to upregulate the expression of TFH 
specific genes (Parker and Metallo 2015, Wang et al. 2015). 
In addition, recurrent loss of function mutations in DNMT3A are present in 10-40% of AITL samples, 
frequently along with Tet2 mutations (Figure 1.1) (Couronne et al. 2012, Palomero et al. 2014, 
Sakata-Yanagimoto et al. 2014, Yoo et al. 2014, Wang et al. 2015). In fact, mutations in these 
epigenetic regulators often co-occur in the same case (Figure 1.1), in contrast to myeloid 
malignancies, in which IDH2  and TET2 mutations are mutually exclusive (Wang et al. 2015). 
 
 
Figure 1.1 – Co-occurrence of frequent mutations in AITL. a, Analysis of the mutational status of RHOA 
G17V, TET2, DNMT3A, and IDH2 in a cohort of 120 AITL (information extracted from published data 
(Palomero et al. 2014, Sakata-Yanagimoto et al. 2014, Yoo et al. 2014, Wang et al. 2015)). Each column 
represents a patient sample; each row represents mutations in each of the genes of interest. b, Quantification 
of the co-occurrence of mutations in RHOA G17V and epigenetic regulators. In the column on the left are the 
cases mutated for RHOA G17V, TET2, DNMT3A, and IDH2 R172; on the upper row the co-occurrence 
indicated by the number of cases on the left category that also carry the mutation in the genes indicated on 
the top (n) and the percentage of co-occurrence calculated from the total number of cases [(%) in bold]. 
Adapted from (Cortés and Palomero 2016). 
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Detection of these epigenetic regulator mutations in blood cells of normal elderly individuals (Xie et 
al. 2014) and in non-tumor cells of AML and PTCL patients (Quivoron et al. 2011, Sakata-
Yanagimoto et al. 2014) suggest their role as an initial or pre-malignant lesion in hematopoietic 
progenitors that could eventually lead to malignant transformation in both the T cell and myeloid 
lineages. Notably, nearly 95% of AITL cases with RHOA G17V allele include mutations in at least 
one of the three aforementioned epigenetic regulators (Figure 1.1) (Cortés and Palomero 2016). 
Based on these findings, a recent study developed a CD4+ T cell mouse lymphoma model that fully 
recapitulates the features associated with human AITL by expressing RHOA G17V in a Tet2−/− 
background (Cortes et al. 2018, Ng et al. 2018). These reports support the two-hit model of AITL 
lymphomagenesis, in which the second hit RHOA mutation drives the full transformation and 
lineage specification of the pre-malignant progenitor cells harboring the first-hit lesion in epigenetic 
regulators. 
Additionally, gene expression profiling studies have implicated TCR signaling dysregulation as a 
major factor in AITL pathogenesis (Iqbal et al. 2014), and sequencing of AITL samples have 
uncovered somatic mutations in genes regulating the TCR activation cascade: PLCG1, 14% 
(Vallois et al. 2016); CD28, 10% (Lee et al. 2015, Rohr et al. 2016, Vallois et al. 2016, Vallois et al. 
2018); FYN, 3% (Palomero et al. 2014, Vallois et al. 2016); VAV1, 4% (Vallois et al. 2016, Abate 
et al. 2017); CARD11, 3% (Vallois et al. 2016) (Figure 1.2). Additionally, a copy number alteration 
(I) study has reported frequent gains in a region that harbors CARD11 (Fujiwara et al. 2008). TCR 
signaling leads to activation of AP-1, NFAT, and NF-κB transcriptional programs and plays a critical 
physiologic role in T cell function (Figure 1.2). In this context, the somatic mutations in the TCR 
regulatory elements that are reported in AITL are mostly activating: mutations in PLCγ, an activator 
of second messenger diacylglycerol (DAG) encoded by PLCG1, promote MALT1 cleavage and 
NFAT activity (Vallois et al. 2016); mutations in CD28, a major co-stimulatory molecule for TCR 
activation encoded by CD28, induce increased NF-κB activity (Lee et al. 2015, Rohr et al. 2016); 
mutations in the SRC family tyrosine kinase FYN, a crucial proximal element of TCR signaling 
cascade encoded by FYN, disrupt the intramolecular inhibitory interaction of the kinase (Palomero 
et al. 2014); mutations in hematopoietic-specific guanine nucleotide exchange factor (GEF) VAV1 
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encoded by VAV1, another significant mediator of TCR signaling, often cause in-frame deletions 
that perturb the autoinhibitory domain of the protein (Abate et al. 2017).  
 
Figure 1.2 – Genes constituting T cell receptor activation pathway are recurrently altered in AITL. 
Schematic of the T cell receptor (TCR) signaling cascade with a simplified representation of the downstream 
signaling mediators. Briefly, TCR engagement leads to activation of LCK and FYN kinases which leads to 
signaling enzymes VAV1 and phospholipase Cγ (PLCγ) docking at Linker of activated T cells (LAT). PLCγ 
generates Inositol trisphosphate (IP3), which ultimately results in NFAT activation, and diacylglycerol (DAG). 
DAG-dependent protein kinase C (PKC) θ then translocates to the plasma membrane and phosphorylates 
CARD11. The phosphorylated CARD11 recruits BCL10 and MALT1 to oligomerize into CBM complex and 
activate canonical NF-κB in a TRAF6 ubiquitin ligase-dependent manner. CD28 costimulatory molecule upon 
activation recruits SH2-containing enzymes, including phosphoinositide 3 kinase (PI3K), and induces 
enhanced signaling, most notably NF-κB activity. For more detailed description of TCR signaling cascade, see 
page 27. Genes that are recurrently altered in AITL are indicated by red box. 
 
Structural abnormalities identified in AITL involve CD28 and VAV1. Multiple studies have described 
CD28 gene fusions, CTLA4-CD28 and ICOS-CD28, while their frequencies in AITL remain 
uncertain (Gong et al. 2016, Rohr et al. 2016, Yoo et al. 2016a, Yoo et al. 2016b, Vallois et al. 
2018). Physiologically, TCR stimulation markedly upregulates CTLA4 and ICOS and 
downregulates CD28 (Chen and Flies 2013). As the promoters for CTLA4 and ICOS control the 
expression of these CD28 chimeric genes, these fusion events may trigger sustained CD28-
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costimulatory signaling (Kataoka et al. 2015). While more often found in PTCL, NOS and ALCL, 
VAV1 fusion gene is also present in AITL and results in the deletion of the negative regulatory 
domain of the protein and consequently increased signaling activity (Abate et al. 2017). 
Anaplastic large cell lymphoma 
ALCL is a general heading for four different entities that differ in clinical presentation and expression 
of the ALK gene rearrangements: ALK-positive ALCL, ALK-negative ALCL, primary cutaneous 
ALCL, and breast implant-associated ALCL (Table 1.1). This section will focus on the more 
common ALK-positive and ALK-negative ALCLs.  
The presence of ALK gene fusions define the ALK-positive ALCL, which account for about half of 
all ALCLs. About 75-85% of ALK fusions found in ALCL join nucleophosmin (NPM1) and ALK. The 
underlying chromosomal translocation of NPM1-ALK, t(2;5)(p23;q35), was the first recurrent 
genetic abnormality described in PTCL (Rimokh et al. 1989). While ALK fusion partners encompass 
more than 20 genes, all variants of ALK chimera demonstrate constitutive ALK tyrosine kinase 
activity and subsequent downstream activation of oncogenic transcription factor STAT3 (Feldman 
et al. 2013, Crescenzo et al. 2015, Hapgood and Savage 2015).  
ALK-negative ALCL shares a common gene expression signature with ALK-positive ALCL that is 
distinct from that of PTCL, NOS (Piva et al. 2010, Piccaluga et al. 2013, Iqbal et al. 2014). A recent 
study has uncovered multiple genomic mechanism in ALK-negative ALCL that can lead to 
oncogenic STAT3 signaling: mutations in JAK1 and STAT3 as well as STAT3-activating gene 
rearrangements that involve non-ALK tyrosine kinase genes, ROS1 and TYK2 (Crescenzo et al. 
2015). These data suggest that ALCLs, regardless of the ALK status, may be driven by a common 
oncogenic mechanism, particularly constitutive STAT3 activation. 
Other aberrant molecular events identified in ALK-negative ALCL include genetic rearrangements 
harboring non-tyrosine kinase genes DUSP22 and TP63 (Feldman et al. 2011, Vasmatzis et al. 
2012), VAV1 gene fusions (Boddicker et al. 2016), and expression of oncogenic truncated 
transcripts of ERBB4 (Scarfo et al. 2016). 
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Extranodal NK/T cell lymphoma, nasal type 
ENKTCL is a lymphoma that most often originates from natural killer (NK) cells, but in some cases, 
from cytotoxic T cells. The most commonly occurring somatic mutations in ENKTCL involve JAK3 
(35%) and RNA helicase gene DDX3X (20%) (Koo et al. 2012, Jiang et al. 2015). Studies have 
also identified mutations in STAT5B and STAT3, supporting the role of JAK/STAT signaling in 
ENKTCL (Kucuk et al. 2015). 
Peripheral T Cell lymphoma, not otherwise specified 
The molecular characteristics of PTCL, NOS vary widely and overlap significantly with other PTCL 
subtypes. The most prominent of such is a sizable portion of PTCL, NOS cases that express some 
TFH immunophenotype and share a gene expression signature (de Leval et al. 2007, Piccaluga et 
al. 2007) and mutational profile with AITL. The recurrent genetic alterations identified in AITL are 
also present in PTCL, NOS in varying frequencies: RHOA G17V (Palomero et al. 2014, Sakata-
Yanagimoto et al. 2014), TET2 and DNMT3A loss (Couronne et al. 2012, Palomero et al. 2014, 
Sakata-Yanagimoto et al. 2014), somatic mutations in PLCG1 (Watatani et al. 2019) and FYN 
(Palomero et al. 2014, Watatani et al. 2019), and mutations and fusions involving VAV1 (Boddicker 
et al. 2016, Abate et al. 2017, Watatani et al. 2019). In particular, 20-30% of PTCL, NOS harbor 
both RHOA G17V and TET2 loss (Palomero et al. 2014, Sakata-Yanagimoto et al. 2014, Watatani 
et al. 2019), the cooperation of which is shown to induce AITL in mice (Cortes et al. 2018, Ng et al. 
2018), and may represent AITL cases that the current diagnostic criteria are unable to capture. 
Reflecting these observations, the most recent diagnostic standard places some cases previously 
designated as PTCL, NOS under the new provisional categories of follicular T cell lymphoma 
(FTCL) and nodal peripheral T cell lymphoma with TFH phenotype (Table 1.1).  
FTCL is a rare subset of such cases that histologically demonstrate a follicular growth pattern. 
Interestingly, about 20% of FTCL cases contain a recurrent t(5;9)(q33;q22) translocation that 
results in ITK-SYK fusion, an activator of constitutive TCR signaling (Streubel et al. 2006, Huang 
et al. 2009, Dierks et al. 2010, Pechloff et al. 2010). 
Ongoing efforts to further classify the remaining non-TFH PTCL, NOS have similarly examined 
gene expression signatures and mutational profiles. Previous large-scale gene expression profiling 
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studies have described two major subgroups of PTCL, NOS based on high expression of either 
GATA3 or TBX21 (Iqbal et al. 2014, Wang et al. 2014). A more recent study that comprehensively 
examined genetic profiles in a large cohort of PTCL, NOS cases reported frequent loss of tumor 
suppressors TP53 (28%) and CDKN2A (13%), which define a new proposed subset characterized 
by marked genomic instability and poorer prognosis. 
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Table 1.2 – Common chromosomal and molecular abnormalities in peripheral T cell lymphoma. 
PTCL Gene Involved Pathway Alleles (Frequency) 
AITL 
TET2 Epigenetic regulation Loss of function (70%) 
DNMT3A Epigenetic regulation Loss of function (10-40%) 
IDH2 Epigenetic regulation R172 (20-45%) 
RHOA 











PLCG1 TCR signaling  SNV (14%) 
VAV1 TCR signaling 
SNV, in-frame deletion,  
gene fusion (4%) 
FYN TCR signaling SNV (3%) 
ALK+ ALCL ALK JAK/STAT 




JAK1 JAK/STAT Activating mutations (15%) 
STAT3 JAK/STAT Activating mutations (10%) 
Tyrosine kinase 
(ROS1, TYK2) 
JAK/STAT Gene fusion (22%) 
VAV1 TCR signaling Gene fusion (16%) 
DUSP22  Rearrangements (30%) 
TP63  Gene fusions (8%) 
PTCL, 
NOS 
TET2 Epigenetic regulation Loss of function (45%) 





FYN TCR signaling SNV (3%) 
VAV1 TCR signaling 
SNV, in-frame deletion,  
gene fusion (11%) 
ITK TCR signaling 
ITK-SYK in 20% of FTCL 
ITK-FER rare 
TP53 Tumor suppressor Loss of function (28%) 
CDKN2A Tumor suppressor Loss of function (13%) 
 
SNV, single nucleotide variant; TCR, T cell receptor. 
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Treatment options and outcome 
As in B cell lymphomas, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and 
CHOP-like combination chemotherapy programs are the standard first-line treatment regimen in 
PTCLs (Figure 1.3). CHOP-based treatments have largely been unsuccessful in PTCL, possibly 
because this conventional lymphoma therapy originates from clinical trials that included 
predominantly B cell NHL, a biologically distinct but much more common disease. In non-ALCL 
PTCLs, CHOP-based therapy achieves complete response (CR) rate of 50% and 5-year overall 
survival of 37% (Abouyabis et al. 2011). Even in anaplastic large cell lymphomas, which may be 
the only PTCL subgroup in which conventional CHOP-like regimens are effective, about 40% of 
patients with ALK-positive disease and over 60% of patients with ALK-negative disease fail to 
survive after 5 years (Savage et al. 2008). Some younger, healthier patients with chemo-sensitive 
disease receive autologous stem cell transplantation (ASCT) in first remission (Figure 1.3) and 
report superior outcomes in some studies (Reimer et al. 2009, d'Amore et al. 2012). However, the 
benefit may be due to patient selection, and most patients are ineligible due to refractory disease 
or comorbidities. 
Given the dismal prognosis under standard treatment options (Figure 1.4), there is a pressing need 
for new therapeutic strategies based on improved understanding of PTCL biology. Ongoing efforts 
to address the prevalent refractoriness of the disease include incorporating novel agents into CHOP 
regimen, developing a new doublet treatment platform by combining agents that have shown 
efficacy in relapsed and refractory PTCL, and further discovering potential drug targets based on 
identification of mutations and relevant pathways. As a result of these endeavors, the US Food and 
Drug Administration (FDA) has approved four novel agents in patients with relapsed or refractory 
PTCL since 2009 (Table 1.3). Encouragingly, a recent clinical trial integrating one of the novel 
drugs that targets CD30 into the traditional regimen has made major advance in the frontline 
therapy against CD30+ PTCLs (Horwitz et al. 2019). Considering that efforts to empirically modify 
CHOP with more dose-intense combination chemotherapy have failed to improve outcomes 
(Escalon et al. 2005, Simon et al. 2010), the success of this trial confirms the potential of the 
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targeted, rationally designed therapy based on the tumor biology. The sections below briefly 
discuss the recent and ongoing ventures to improve outcomes in PTCL. 
 
 
Figure 1.3 – Treatment algorithm for initial presentation of peripheral T- cell lymphoma. AITL, 
angioimmunoblastic T cell lymphoma; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma 
kinase; autoSCT, autologous stem cell transplant; BIA, breast implante-associated; CHOEP, 
cyclophosphamide + doxorubicin + vincristine + etoposide + prednisone; CHOP, cyclophosphamide + 
doxorubicin + vincristine + prednisone; IVE, ifosfamide + epirubicin + etoposide; CR, complete response; DA-
EPOCH, dose-adjusted etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin; hyperCVAD, 
cyclophosphamide + vincristine + doxorubicin + dexamethasone – alternating with methotrexate + cytarabine; 
PTCL-NOS, peripheral T cell lymphoma, not otherwise specified; PR, partial response; RT, radiation therapy. 




Figure 1.4 – Overall survival of patients with the common subtypes of peripheral T cell lymphoma. 
Peripheral T cell lymphoma, not otherwise specified, 32%; Angioimmunoblastic T cell lymphoma, 32%; Adult 
T cell leukemia/lymphoma, 14%; Anaplastic large cell lymphoma, ALK+, 70%; Anaplastic large cell lymphoma, 
ALK-, 49%. Adapted from (Vose et al. 2008) 
 
FDA-approved agents in relapsed and refractory peripheral T cell lymphomas 
Starting with the antifolate pralatrexate approval in 2009, the FDA has approved four new agents 
for relapsed and refractory PTCL based on the phase II trials that showed statistically significant 
efficacy (Table 1.3). In 2011, the FDA approved the histone deacetylase (HDAC) inhibitor 
romidepsin for its efficacy shown in 130 patients whose disease had failed to respond to at least 
one prior systemic therapy with PTCL (Coiffier et al. 2014). Treatment with romidesin achieved an 
objective response rate of 25%, including 15% with CR, and the responses lasted a median of 
greater than two years. Brentuximab vedotin, another novel agent approved for PTCL in 2011 by 
the FDA, is a CD30-targeted immunoconjugate that demonstrated a high response rate of 85% in 
a phase II study of 58 patients with CD30+ ALCL who relapsed after prior therapy (Pro et al. 2012). 
Brentuximab vedotin was approved for relapsed, refractory systemic ALCL, but not for patients with 
other subtypes of PTCL. Most recently in 2014, FDA approved belinostat, a novel pan-HDAC 
inhibitor based on a phase II trial of 129 patients with relapsed and refractory PTCL that 




Table 1.3 – Novel agents approved for relapsed/refractory peripheral T cell lymphomas 
Approved 
Agent 
Indications Mechanism of Action 
Outcomes  
(ORR, CR, DOR) 
Belinostat PTCL HDAC inhibitor 
26%, 11%, 13.6 mo 




α-CD30 linked to auristatin 
(antitubulin agent) 
86%, 57%, 13.2 mo  
(Pro et al. 2012) 
Pralatrexate PTCL DHFR/thymidylate synthase inhibitor 
29%, 11%, 10.1 mo 
(O'Connor et al. 2011) 
Romidepsin PTCL HDAC inhibitor 
25%, 15%, 28 mo 
(Coiffier et al. 2014) 
38%, 18%, 8.9 mo 
(Piekarz et al. 2011) 
PTCL, peripheral T cell lymphoma; ALCL, anaplastic large cell lymphoma; ORR, objective response rate; CR, 
complete response; DOR, duration of response; mo, months. 
 
Incorporating novel agents into the conventional CHOP regimen  
Approval of these novel agents has led to attempts to improve upon the CHOP backbone of the 
frontline PTCL therapy (Table 1.4). Several large randomized studies have been recently 
completed, are ongoing, or have been planned. Most significantly, the recent announcement of 
results from the phase III ECHELON-2 trial of A+CHP (brentuximab vedotin, cyclophosphamide, 
doxorubicin, prednisone) versus conventional CHOP chemotherapy assessing 452 patients with 
untreated CD30+ PTCL demonstrated A+CHP’s advantage in progression-free survival (PFS) and 
an overall survival (OS), resulting in a first-line FDA approval of this regimen (Horwitz et al. 2019). 
The success of brentuximab vedotin in CD30+ PTCL shows the promise of properly targeted 
therapies. 
Other attempts to use novel agents in combination with CHOP have met with limited success. 
Phase III trials of chemotherapy combining CHOP with alemtuzumab, a humanized antibody 
against mature lymphocyte marker CD52, failed to show significant difference in PFS and OS 
compared to CHOP (Altmann et al. 2018). A phase Ib/II trial combined romidepsin with CHOP (Ro-
CHOP) for frontline treatment of 37 patients with PTCLs and demonstrated a 30-month PFS of 41% 
with OS 70.7%, albeit with more toxicity (Dupuis et al. 2015). Currently, a phase III trial comparing 




Table 1.4 – Key ongoing and recently completed phase III trials 






Alemtuzumab + CHOP vs CHOP  
No significant difference in 
PFS and OS. Increased 






A+CHP vs CHOP 
Median PFS: 48.2 mo in 
A+CHP vs 20.8 mo in CHOP 






Ro-CHOP vs CHOP 







Hypomethylating agent Azacitidine vs 







Aurora A kinase inhibitor Alisertib vs 
pralatrexate vs romidepsin vs 
gemcitabine 
Alisertib not statistically 
significantly superior to the 
comparator arm (O'Connor et 
al. 2019b) 
CHOP, cyclophosphamide + doxorubicin + vincristine + prednisone; PFS, progression-free survival; OS, 
overall survival; A+CHP, brentuximab vedotin + cyclophosphamide + doxorubicin + prednisone; mo, months; 
Ro-CHOP, romidepsin + CHOP. 
 
Targeted therapy in peripheral T cell lymphomas  
The identification and functional characterization of ALK gene fusions, the prevalent, subtype-
defining genetic marker of ALK-positive ALCL, has enabled a therapy based on an understood 
mechanism and defined target. In non-small cell lung cancers, a small molecule tyrosine kinase 
inhibitor crizotinib successfully targets tumors bearing ALK gene rearrangements (Shaw et al. 
2013). A small study testing crizotinib in 11 patients with refractory ALK-positive lymphoma 
demonstrated an objective response rate (ORR) of 91%, OS of 72.7%, and PFS of 63.7% at 2 
years (Gambacorti Passerini et al. 2014). In addition, 3 patients experienced a CR for greater than 
30 months under continuous crizotinib administration. Given the durable efficacy of the drug, 
crizotinib is now offered in clinic to patients with ALK-positive ALCL that do not respond to standard 
therapy or brentuximab vedotin (Figure 1.5).  
The prevalent TET2 mutations in AITL and PTCL, NOS are another promising therapeutic target. 
With the report of benefits of hypomethylating agents in TET2-mutated myeloid malignancies (Bejar 
et al. 2014), recent and ongoing studies have examined the efficacy of those drugs in AITL. A 
retrospective case series of 12 AITL patients treated with a hypomethylating agent azacytidine 
reported a 75% ORR including 50% CRs (Lemonnier et al. 2018), prompting initiation of a phase 
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III trial comparing azacytidine with the investigator’s choice of romidepsin, bendamustine, or 
gemcitabine (NCT03593018). In addition, an ongoing phase Ib/II trial of romidepsin and azacytidine 
combination (NCT01998035) recently reported an ORR of 73% in TCL with 55% CRs (Falchi et al. 
2019, O'Connor et al. 2019a). 
In addition, several early phase single-agent clinical trials have demonstrated clinical efficacy of 
targeting the TCR signaling. A case series of 12 patients with AITL who were treated with 
cyclosporin A, a calcineurin inhibitor that abrogates TCR signaling effector pathways such as 
NFAT, demonstrated response in 8 patients including 3 with CR (Advani et al. 2007). In a phase I 
study, a treatment with phosphoinositide 3 kinase (PI3K) inhibitor duvelisib in 16 patients with 
refractory or relapsed PTCL achieved a 50% ORR including 3 CRs (Horwitz et al. 2018a). In 
addition, an ongoing phase Ib/II study combining either romidepsin or bortezomib with duvelisib 
(NCT02783625) reported an encouraging ORR of 55% (12/22 patients) and CR rate of 27% (6/22) 
in refractory or relapsed PTCL (Horwitz et al. 2018b). A planned phase II study will test efficacy of 
duvelisib in 120 patients with refractory or relapsed PTCL (NCT03372057). 
Lastly, based on the preclinical activity of JAK/STAT inhibitors, two ongoing phase II trials are 
testing the oral JAK inhibitor ruxolitinib. One study in relapsed or refractory B cell NHL and PTCL 
(NCT01431209) has enrolled 71 patients, and the other study exclusively in relapsed or refractory 
T cell lymphoma (NCT02974647) is enrolling a planned 52 patients. 
Ongoing and recently completed single-agent clinical trials in PTCL are summarized in Table 1.5. 
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Figure 1.5 – Treatment algorithm for relapsed/refractory peripheral T- cell lymphoma. AITL, 
angioimmunoblastic T cell lymphoma; ALCL, anaplastic large cell lymphoma; AlloSCT, allogenic stem cell 
transplantation; autoSCT, autologous stem cell transplantation; BV, brentuximab vedotin; CR, complete 
response; GVD, gemcitabine + vinorelbine + pegylated liposomal doxorubicin; HDACi, histone deacetylase 




Table 1.5 – Single-agent therapies under investigation for relapsed/refractory peripheral T cell 
lymphomas 
Single-Agent Mechanism of Action Phase Clinical Trial ID 
Endostar Angiogenesis inhibitor II NCT02520219 
E7777 
Diphtheria Toxin Fragment-Interleukin-2 Fusion 
protein 
II NCT02676778 
Selinexor Selective inhibitor of nuclear export II NCT02314247 
Tipifarnib Farnesyltransferase inhibitor II NCT02464228 
Darinaparsin Organic arsenic compound II NCT02653976 
Ixazomib Proteasome inhibitor II NCT02158975 
Forodesine PNP inhibitor I/II NCT01776411 
Ruxolitinib JAK inhibitor II NCT01431209 
  II NCT02974647 
Temsirolimus mTOR inhibitor I NCT01614197 
Duvelisib PI3K inhibitor II NCT03372057 
Carfilzomib Proteasome inhibitor I NCT01336920 
Panobinostat Pan-deacetylase inhibitor II NCT01261247 
Clofarabine  DNA synthesis inhibitor I/II NCT00644189 
MK2006  AKT inhibitor II NCT01258998 
Sorafenib  Multikinase inhibitor II NCT00131937 
Alefacept Immunosuppressive dimeric fusion protein I NCT00438802 
Pembrolizumab PD-1 antibody II NCT02535247 
Fenretinide Synthetic retinoid derivative II NCT02495415 
MEDI-570 Anti-ICOS monoclonal antibody I NCT02520791 
EDO-S101 Alkylating HDAC inhibitor I NCT02576496 
ALRN-6924 MDM2/MDMX antagonist I/II NCT02264613 




II. NF-κB signaling in lymphoma 
 
Overview of NF-κB signaling pathway 
Nuclear factor (NF)-κB is a family of inducible transcription factors critical for a variety of cellular 
responses. In the steady state, the members of the family form various homodimers and 
heterodimers that are kept inactive in the cytoplasm by the C-terminal precursor domain or the 
binding of inhibitory IκB proteins. Physiologic activation of NF-κB occurs in response to stimulation 
of a wide range of surface receptors and via two common signaling pathways, namely the canonical 
or the alternative pathway. Both pathways are based on inducible degradation of the C-terminal 
precursor domain or the IκB proteins following IκB-kinase (IKK) complex-mediated 
phosphorylation. Subsequent to the removal of IκB from the NF-κB dimers, the NF-κB transcription 
factors translocate to the nucleus and bind to the DNA κB sites to induce activation of target genes.  
Biochemical control of NF-κB via IκB, rather than transcriptional regulation, provides a rapid 
molecular switch that enables instant launch of pre-formed transcription complexes in response to 
urgent stimuli such as pathogens. In the developmental paradigm, the biochemical induction of 
transcriptional program also resolves the infinite regression paradox of how expression of the first 
tissue specific transcription factor occurs, if a tissue-specific transcription factor itself requires a 
tissue-specific transcription factor (Zhang et al. 2017b).  
Under physiologic conditions, NF-κB activation is a transient and highly regulated process and 
plays a particularly crucial role in development, function, and survival of immune cells. Sections 
below highlight key molecules and steps of the pathway.  
Components of the NF-κB System 
NF-κB is a family of related proteins that, as a homo- and hetero-dimer, bind to the enhancers or 
promoters of hundreds of genes via the κB site, a nearly palindromic DNA sequence with a 
consensus of 5’-GGGRNWYYCC-3’ (http://www.bu.edu/nf-kb/gene-resources/target-genes/) (Sen 
and Baltimore 1986, Lenardo et al. 1987). The NF-κB family consists of five proteins that share N-
terminal Rel homology domain (RHD) followed by nuclear localization sequence (NLS): p105 
(precursor of p50), p100 (precursor of p52), Rel A (p65), Rel B, and c-Rel (Figure 1.6). Functions 
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of RHD include sequence-specific DNA binding, dimerization, and inhibitory protein binding, all 
three of which are essential for the proper regulation and operation of the pathway. To date, 13 of 
the 15 potential NF-κB dimers have been described. The combinatorial diversity of the dimers, 
which results in molecules of different affinities to the variants of the κB site and to the co-
transcriptional factors, may contribute to the distinct but overlapping gene regulatory patterns 
observed in NF-κB (Smale 2012). 
 
 
Figure 1.6 – Components of the NF-κB System. Members of the NF-κB, IκB, and IKK proteins family. The 
number of amino acids in each human protein is indicated on the right. Post-translational modifications that 
influence IKK activity or transcriptional activation are indicated with P and Ub for phosphorylation and 
acetylation. RHD, Rel homology domain; TAD, transactivation domain; LZ, leucine zipper domain; HLH, helix-
loop-helix domain; Zn, zinc finger domain; CC1/2, coiled-coil domains; NBD, NEMO-binding domain; AnkR, 
ankyrin repeats; DD, death domain; PEST, region rich in the amino acids proline, glutamic acid, serine, and 
threonine. Adapted from (Zhang et al. 2017b). 
 
The five NF-κB subunits are synthesized either as mature proteins with C-terminal transactivation 
domains (TADs) in the case of Rel A, Rel B, and c-Rel or as precursors with C-terminal ankyrin 
repeats (AnkR) that are post-translationally cleaved in the case of p105 (NFKB1) and p100 
 24 
(NFKB2). AnkR is a hallmark domain of a dedicated set of inhibitory proteins and domains 
comprising the “Inhibitor of κB” (IκB) family (Figure 1.6). The members of the family–IκBα, IκBβ, 
IκBε, BCL-3, IκBz, IκBNS, and the C-terminal portions of the precursor proteins p105 (IκBγ) and 
p100 (IκBδ)–sequester the NF-κB proteins in the cytoplasm in the unstimulated steady state by 
masking their NLS. 
NF-κB dimers are relieved from the inhibitory factors by IKK phosphorylation-mediated degradation 
of the IκB proteins or by limited proteolysis that eliminates the C-terminal portion of p100 and p105 
to make p52 and p50 respectively. The proteolysis occurs constitutively in p105 but only after 
phosphorylation events in p100 (Hayden and Ghosh 2008). The signaling events that lead to 
removal of inhibitory factors can occur by the canonical pathway or the alternative pathway (Figure 
1.7). The two pathways rely on a different set of IKKs, the kinases that phosphorylate IκB proteins 
(Figure 1.6). In the canonical pathway, IKKα, IKKβ, and NEMO form a classical three-factor IKK 
complex, in which IKKβ phosphorylates the IκB proteins. On the other hand, the alternative pathway 
utilizes a dimer of IKKα to phosphorylate p100. P100, which is mainly complexed with RelB, blocks 





Figure 1.7 – Canonical and alternative pathway of NF-κB activation. a, Activation of the canonical NF-κB 
pathway. The stimuli that activate the canonical pathway include the antigen receptors TCR/BCR, 
proinflammatory cytokines (IL-1, IL-17, and TNF-α), and pathogen-associated molecular patterns that bind to 
TLRs (1). IκB proteins become phosphorylated at two serine residues by the activated IKK complex and 
subsequently polyubiquitinated by K48-linkage (2), which triggers proteasomal degradation (3). IκB demolition 
reveals NLS of the NF-κB dimers, which then translocate into the nucleus and activate target genes (4). B, 
Activation of the alternative NF-κB pathway. The members of TNF receptor superfamily, including CD40, the 
lymphotoxin β receptor, and the BAFF receptor trigger the alternative pathway (A). This pathway culminates 
in the NIK-mediated activation of IKKα dimer (B), which can directly phosphorylate p100 (C), inducing 
proteasomal partial proteolysis of p100 to remove the inhibitory ankyrin repeats and to generate p52 (D). The 
p52 protein preferentially dimerizes with RelB to translocate into the nucleus I. Adapted from (Jost and Ruland 
2007). 
 
The canonical pathway 
In the canonical NF-κB pathway, also known as the classical pathway, various signaling cascades 
that involve different adaptor molecules ultimately converge on the classical IKK complex, a 
cytosolic IKK holoenzyme containing a non-catalytic regulatory subunit NEMO (“NF-κB essential 
modifier,” also called IKKγ) and two kinase subunits IKKα and IKKβ. The upstream signaling 
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apparatuses transmit the stimuli to the IKK complex by oligomerizing into a polyubiquitinated 
signalosome, to which NEMO anchors the two kinase subunits by interacting with the ubiquitin 
chains. Following the activation of the IKK complex, the catalytic IKKβ subunit phosphorylates IκBα 
on Ser 32 and Ser 36, or IκBβ on Ser 19 and Ser 23. The phosphorylated IκB proteins then undergo 
proteasomal degradation triggered by the SCFβ−TrCP E3 ubiquitin ligase-mediated, K48-linked 
polyubiquitination and release the canonical NF-κB transcription factor, most famously the p50-p65 
heterodimer (Hayden and Ghosh 2012) (Figure 1.7a). 
One of the most notable examples of the canonical NF-κB activation is antigen receptor signaling 
in T cells triggered by the ligation of the TCR and the costimulatory molecule CD28. Following the 
receptor engagement, FYN and LCK kinases phosphorylate immunoreceptor tyrosine-based 
activation motif (ITAM) on CD3ζ, which recruits and activates ZAP70 kinase. ZAP70 promotes 
signal diversification by phosphorylating Linker for activation of T cells (LAT), a signaling hub that 
forms numerous interactions with other signaling molecules including phospholipase Cγ (PLCγ). 
Activated PLCγ hydrolyzes plasma membrane phospholipid phosphatidylinositol 4,5-bisphosphate 
(PIP2) into two second messengers, diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). In 
parallel, CD28 ligation results in phosphorylation of PIP2 by PI3K into phosphatidylinositol 3,4,5-
trisphosphate (PIP3), which recruits PDK1 to become auto-phosphorylated. PKCθ, which binds to 
both DAG and phosphorylated PDK1, then translocates to the plasma membrane and 
phosphorylates CARD11. Phosphorylated CARD11 undergoes a structural change that allows the 
formation of the CARD11-BCL10-MALT1 (CBM) signaling complex, a shared intermediary of TCR 
and BCR signaling pathway that leads to NF-κB activation (Smith-Garvin et al. 2009) (Figure 1.2). 
The assembled CBM complex serves as a central scaffold that recruits ubiquitination and 
phosphorylation mediators in close proximity to generate signaling events. In conjunction with the 
E2 ubiquitin-conjugating enzymes ubiquitin-conjugating enzyme 13 (UBC13) and ubiquitin-
conjugating enzyme variant 1A (UEV1A), the E3 ubiquitin ligases–tumor necrosis factor (TNF) 
receptor-associated factor 2 (TRAF2) and TRAF6, cellular inhibitor of apoptosis protein 1 (cIAP1) 
and cIAP2, and the linear ubiquitin chain assembly complex (LUBAC)–catalyze K63-linked and M1-
linked ubiquitination of multiple proteins, including BCL10 and MALT1 themselves. Several of these 
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E3 ligases may have at least partially redundant functions or operate only in specific settings, as 
some studies found TRAF6 and LUBAC to be dispensable under certain conditions. The 
ubiquitination events enable the signaling platform to engage the TGFβ-associated kinase 1 (TAK1) 
complex, which includes ubiquitin-binding proteins TAK1-binding protein 2 (TAB2) and TAB3, and 
the classical IKK complex, a regulatory subunit NEMO of which associates with ubiquitin and 
becomes further ubiquitinated by TRAF6 and LUBAC. The recruited IKK complex becomes 
activated via TAK1-mediated and trans-auto-phosphorylation and subsequently catalyzes IκBα 
phosphorylation, which triggers K48-linked polyubiquitination followed by proteasomal degradation. 
Relieved from the inhibitory protein, NF-κB transcription factors then accumulate in the nucleus and 
activate target genes (Lork et al. 2019, Ruland and Hartjes 2019).  
Newly expressed genes in response to NF-κB activation promote lymphocyte proliferation and 
specific immune functions such as generation of cytokines in T cells. Aberrant activation of NF-κB 
can foster immunodeficiency, autoimmune diseases, or lymphoid malignancies. Therefore, to 
tightly modulate the signaling, several deubiquitinases negatively regulate the pathway by 
removing ubiquitin chains from the signaling platform. TNF-α inducible protein 3 (TNFAIP3, also 
known as A20) and CYLD (cylindromatosis) eliminate the K63-linked ubiquitin chains, and more 
recently described OTULIN cleaves the M1-linked linear ubiquitin chains. NF-κB activation 
transcriptionally targets some of these deubiquitinases, as well as the IκB proteins, and establishes 
a negative feedback loop (Sun 2008, Keusekotten et al. 2013).  
In addition to the antigen receptor in lymphocytes, the surface receptors that activate the canonical 
NF-κB pathway include Toll-like receptor (TLR), cytokine receptors, and tumor necrosis factor 
receptor (TNFR).  
The alternative pathway 
In the alternative pathway, or the non-canonical pathway, a dimer of IKKα controls the degradation 
of the inhibitory peptide masking the NF-κB transcription factor, independent of IKKβ, IKKγ, or the 
classical IKK complex. The most well-described NF-κB dimer of the alternative pathway is p52-
RelB, which in resting state exists in the precursor form p100-RelB. IKKα phosphorylates p100 on 
serines 866 and 870 and induces proteasomal processing to p52, following selective proteolysis of 
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the C-terminal AnkR-containing precursor inhibitory domain, sometimes called IκBδ. The mature 
p52-RelB dimer then localizes to the nucleus and activates the NF-κB transcriptional program 
(Hayden and Ghosh 2008) (Figure 1.7b). 
Activation of IKKα depends on the turnover of its activating kinase NF-κB-inducing kinase (NIK). 
Constitutively active, NIK is negatively regulated by TRAF3-mediated polyubiquitination that 
induces proteasomal degradation. The alternative pathway inducers, via various mechanisms, 
removes TRAF3 and thereby stabilizes NIK so it can phosphorylate IKKα. Whereas the canonical 
pathway generates rapid and transient response through oligomerization process, the alternative 
pathway operates under the control of protein destruction and re-synthesis and therefore in a 
slower and more sustained kinetics (Hayden and Ghosh 2008).  
The receptors that activate the alternative pathway, such as Limphotoxin β receptor (LTβR), 
Receptor activator of nuclear factor κB (RANK), B cell-activating factor receptor (BAFFR), and 
CD40, mostly belong to the TNFR superfamily. Upon ligation of the receptor, CD40, for example, 
recruits TRAF2, which targets TRAF3 to proteasomes or complexes with it to displace NIK by 
allosteric competition (Hayden and Ghosh 2012). These receptors all share the common 
downstream NF-κB dimer p52-RelB but engender distinct transcriptional response. LTβR promotes 
the development of peripheral lymph nodes and Peyer’s patches, RANK regulates bone formation 
and dendritic cell functions, BAFF drives peripheral B cell differentiation and survival, and CD40 
controls B cell activation, maturation, germinal center formation, somatic mutation, and class 
switching. How a single dimer can produce such diverse outcomes is unknown (Zhang et al. 
2017b). 
Physiologic role of NF-κB signaling in normal lymphoid tissue 
Studies have unequivocally demonstrated the pivotal physiologic role of NF-κB in the immune 
system. Mouse knockouts and human genetic disorders of the key NF-κB components 
predominantly result in immunological defects (Gerondakis et al. 2006, Steiner et al. 2018), 
inducers of NF-κB activation are frequently cytokines, antigens, and pathogens (Hayden and 
Ghosh 2012), and the transcriptional targets of the pathway include hundreds of immunity-related 
genes (http://www.bu.edu/nf-kb/gene-resources/targetgenes/).  
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Congruently, NF-κB plays an essential role in every facet of lymphocyte biology, including but not 
limited to development, activation, proliferation, and survival (Vallabhapurapu and Karin 2009, 
Gerondakis et al. 2014). The NF-κB target genes relevant for lymphocyte biology include positive 
cell-cycle regulators, antiapoptotic factors, and receptor ligands such as cytokines and 
chemokines. The cell-cycle regulators such as cyclin D1, cyclin D2, c-myc, and c-myb drive 
lymphocyte division (Duyao et al. 1992, Toth et al. 1995, Hinz et al. 1999, Romashkova and 
Makarov 1999) with the help of proliferation and survival signals provided by cytokine targets 
including IL-2, IL-6, and CD40L in both autocrine and paracrine fashion. NF-κB also directly induces 
survival via expression of caspase inhibitors of the cIAP family, the BCL2 family members A1 and 
BCL-XL, and cellular FLICE inhibitor protein (c-FLIP) (Thome and Tschopp 2001, Karin and Lin 
2002).  
The diverse expression patterns of these target genes result in a variety of functional outcomes in 
different stages of lymphocytes. In T cells, constitutive NF-κB activity for survival occurs at all 
stages of thymocyte differentiation and particularly in the double negative phase during the pre-
TCR assembly (Gerondakis et al. 2014). NF-κB also participates in T cell proliferation and survival 
following TCR activation via myc-induced growth, IL-2 signaling, and death receptor pathways 
(Kontgen et al. 1995, Grumont et al. 2004, Jones et al. 2005) and contributes to the development 
and functional divergence of different helper T cell subsets (Oh and Ghosh 2013). B cell maturation 
requires both canonical and non-canonical NF-κB pathways from early stages of development. NF-
κB activation promotes the transition from large to small pre-B cells (Jimi et al. 2005), controls the 
production of λ-chain B cells (Derudder et al. 2009), triggers anti-apoptotic signals in response to 
BCR cross-linking and BAFFR signaling (Castro et al. 2009), and enables antibody production and 
class-switching of mature B cells (Manis et al. 2002).  
Pathogenic activation of NF-κB in lymphoid neoplasms 
As NF-κB promotes lymphocyte proliferation and survival, its aberrant oncogenic activation has 




Diffuse large B cell lymphoma 
Diffuse large B cell lymphoma represents the most prevalent type of NHL, comprising about 40% 
of the cases, and consist of three discrete subtypes: germinal center B cell-like (GCB) DLBCL, 
activated B cell-like (ABC) DLBCL, and primary mediastinal B cell lymphoma (PMBL), which arise 
from different stages of normal B cell differentiation and utilize distinct oncogenic pathways (Staudt 
and Dave 2005).  
Constitutive activation of the NF-κB pathway is a hallmark of ABC DLBCL. Gene expression 
profiling studies revealed enrichment of NF-κB target genes in ABC DLBCL tumor biopsy samples 
and cell line models (Davis et al. 2001), and genomic profiling identified genetic aberrations 
activating NF-κB in more than two thirds of the patients (Ngo et al. 2011, Pasqualucci et al. 2011). 
Consistently, NF-κB inhibition using a non-degradable form of IκBα or a small molecule IKKβ 
inhibitor resulted in apoptosis in ABC DLBCL cell lines (Davis et al. 2001, Lam et al. 2005).  
NF-κB-related genes aberrations detected in ABC DLBCL include activating mutations in the 
regulators of the BCR – CARD11 (9%) (Lenz et al. 2008) and CD79 (21%) (Davis et al. 2010) – 
and TLR – MYD88 (30%) (Ngo et al. 2011) – as well as inactivating mutations in the negatively 
regulating deubiquitinase TNFAIP3 (30%) (Compagno et al. 2009, Kato et al. 2009). Recently, a 
report of oncogenic BCR signaling supercomplex (MyD88-TLR9-BCR) described a NF-κB-
activating multiprotein signalosome in ABC DLBCL that clusters BCR, CD79a/b, MyD88, and 
downstream signaling effectors such as IKKs on the endolysosome membrane to facilitate 
synergistic signaling and crosstalk (Phelan et al. 2018). The clinical success of ibrutinib, a Bruton’s 
tyrosine kinase (BTK) inhibitor that blocks BCR signaling, evidences the oncogenic mechanism of 
chronic BCR activation in these tumors (Wilson et al. 2015).  
NF-κB signaling in ABC DLBCL results in the expression of IRF4 (Lam et al. 2005), which drives 
plasmacytic differentiation in both normal lymphocytes and in malignant cells (Klein et al. 2006, 
Sciammas et al. 2006, Shaffer et al. 2008). Interestingly, the tumor cells escape the cell cycle arrest 
typical in normal plasma cells by halting the differentiation at the plasmablastic stage (Calado et al. 
2010), thanks to the frequent genetic lesions that inactivate Blimp-1, another plasma cell 
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differentiation factor that cooperates with IRF4 in normal B cells (Tam et al. 2006, Schmidlin et al. 
2008, Mandelbaum et al. 2010).  
Additionally, high expression of IL-6 in response to NF-κB signaling in ABC DLBCL generates an 
autocrine signaling loop via activation of JAK-STAT pathway. IL-6 binds to its own receptors and 
triggers JAK-STAT activation and STAT3 phosphorylation, causing interaction between 
31hosphor-STAT3 and NF-κB heterodimers to enhance transactivation of NF-κB target genes 
(Yang et al. 2007, Lam et al. 2008).  
In contrast, GCB DLBCL demonstrate little NF-κB activation (Compagno et al. 2009), and PMBL, 
while the details are still unclear, show NF-κB activity similar to Hodgkin lymphoma (Rosenwald et 
al. 2003, Savage et al. 2003, Schmitz et al. 2009). 
Hodgkin lymphoma  
The defining feature of Hodgkin lymphoma is the presence of malignant Hodgkin and 
Reed/Sternberg (HRS) cells surrounded by a sea of inflammatory cells from a variety of 
hematopoietic lineages. In approximately a half of Hodgkin lymphoma cases, the HRS cells harbor 
EBV, which encodes a potent NF-κB activator latent membrane protein 1 (LMP1). Constitutive NF-
κB activity is also present in the other half of EBV-negative Hodgkin lymphoma, evidenced by high 
levels of nuclear p50-p65 heterodimers (Bargou et al. 1996) and IκBα super repressor-induced 
toxicity (Bargou et al. 1997). Mutational profiling of Hodgkin lymphoma later revealed inactivating 
mutations in negative regulators of the canonical NF-κB pathway, including IκBα-encoding NFKBIA 
(20%) (Cabannes et al. 1999, Emmerich et al. 1999, Jungnickel et al. 2000, Lake et al. 2009), IκBε-
encoding NFKBIE (Emmerich et al. 2003), and TNFAIP3 (44%) (Schmitz et al. 2009). In addition, 
some reports have documented evidence in support of a role for the inflammatory milieu 
surrounding the malignant cells in contributing to the NF-κB activation in the malignant cells via 
paracrine signaling (Schwab et al. 1982, Gruss et al. 1994, Carbone et al. 1995, Pinto et al. 1996, 
Molin et al. 2002). 
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MALT lymphoma 
Mucosa-associated lymphoid tissue (MALT) lymphoma, a form of marginal zone lymphoma, occurs 
most commonly in the stomach but also in a variety of anatomical sites near mucosal surfaces. 
MALT lymphoma frequently arises in the setting of extrinsic BCR activation attributable to 
autoimmune reactions induced by infectious agents such as Helicobacter pylori, Chlamydia psittaci, 
Campylobacter jejuni, Borellia burgdorferi, and hepatitis C virus (Ferreri and Zucca 2007). 
Remarkably, eradication of H. pylori by antibiotic treatment causes sustained complete remissions 
in many low-grade gastric MALT lymphoma patients (Wotherspoon et al. 1993). 
However, a substantial portion of cases fail to regress after eradication of the underlying extrinsic 
cause, suggesting an acquisition of antigen independent growth. Several chromosomal 
translocations that trigger intrinsic oncogenic NF-κB activity have been described in MALT 
lymphoma. About 25% of gastric MALT lymphoma and 40% of lung MALT lymphoma contain a 
t(11:18) translocation that results in a fusion protein cIAP2-MALT1 (Akagi et al. 1999, Dierlamm et 
al. 1999, Morgan et al. 1999, Streubel et al. 2004). Less commonly, a t(14;18) translocation (7% in 
ocular adnexa and 6% in lung) and a t(1;14) translocation (9% in lung and 4% in stomach) induce 
overexpression of MALT1 and BCL10 protein respectively by juxtaposing the genes encoding them 
with the immunoglobulin heavy chain (IgH) locus (Willis et al. 1999, Zhang et al. 1999, Sanchez-
Izquierdo et al. 2003). Splenic hyperplasia and increased and constitutive NF-κB activity in mice 
harboring these genetic rearrangements (Baens et al. 2006, Li et al. 2009) coincide with the 
essential roles of MALT1 and BCL10 in BCR-triggered NF-κB activation (Ruland and Hartjes 2019).  
The cIAP2-MALT1 fusion protein aberrantly activates both the canonical pathway and the 
alternative pathway. Mechanistically, it constitutively activates canonical NF-κB pathway via 
heterotypic interaction between the BIR1 domain of the cIAP2 and the C-terminal region of MALT1 
that results in auto-oligomerization (Zhou et al. 2005, Lucas et al. 2007). Reminiscent of the NF-
κB-activating artificial MALT1 dimers (Lucas et al. 2001, Sun et al. 2004, Zhou et al. 2004), the 
oligomerized fusion proteins may serve as a multivalent platform for the recruitment of the ubiquitin 
ligases like TRAF6 (Zhou et al. 2005, Noels et al. 2007) and ubiquitin-binding signaling factors such 
as IKK complex (Gyrd-Hansen et al. 2008), ultimately facilitating the NF-κB signaling. In addition, 
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cIAP2-MALT1 oligomerization can activate the paracaspase function of the fusion protein’s MALT1 
moiety, cleaving TNFAIP3 and CYLD and eliminating the negative regulators of the pathway 
(Coornaert et al. 2008, Staal et al. 2011). A positive feedback loop may exist between cIAP2-
MALT1 and NF-κB activation, as the expression of the fusion protein is under the control of the 
cIAP2 promoter, an NF-κB target (Hosokawa et al. 2005). 
The alternative pathway activation by cIAP2-MALT1 fusion arise from its interaction with NIK. The 
cIAP2 moiety recruits NIK and places it in close proximity of MALT1 protease domain, which 
cleaves NIK at Arg 325. The resulting C-terminal NIK fragment resists TRAF3-dependent 
proteasomal degradation but maintains the kinase activity to constitutively activate the signaling 
(Rosebeck et al. 2011). 
Multiple myeloma 
Multiple Myeloma (MM) is an aggressive malignancy derived from plasmacytic cells dwelling in the 
bone marrow and represents the second most prevalent hematological malignancy. Gene 
expression profiling studies from as early as 2007 have demonstrated the role of deregulated NF-
κB activity in MM. A distinct patient cluster characterized by NF-κB enrichment responded 
substantially better to bortezomib, a proteasome inhibitor that blocks IκB degradation, as compared 
to other patient groups (Chng et al. 2007). Later studies revealed molecularly heterogeneous 
mechanisms of NF-κB activation in MM. 
Reports of NF-κB-activating mutations in MM emerged as early as in 2007, mapping close to 20% 
of genetic mutations onto various regulators and effectors of NF-κB signaling (Annunziata et al. 
2007, Keats et al. 2007). Subsequent sequencing studies substantiated the prevalence of NF-κB-
activating mutations in a diverse set of genes, ranging from those in the canonical pathway such 
as TLR4, IKBKB (encoding IKKβ), CARD11, CYLD, and TNFAIP3, to those in the alternative 
pathway including MAP3K14 (encoding NIK) and TRAF3 (Chapman et al. 2011, Lohr et al. 2014, 
Troppan et al. 2015, Walker et al. 2015). Signals from the tumor microenvironment, including 
physical cell-cell communications and autocrine and paracrine soluble factors like IL-1β, IL-6, and 
TNF-α, augments the NF-κB signaling in both tumor and non-tumor cells (Hideshima et al. 2007, 
Fairfield et al. 2016). Importantly, the therapeutic efficacy of immunomodulatory drugs such as 
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thalidomide and lenalidomide in MM has been at least in part attributed to their ability to inhibit the 
aforementioned pro-inflammatory cytokines (Quach et al. 2010). Additional NF-κB-activating tumor 
microenvironment factors documented in MM pathogenesis include BAFF (Moreaux et al. 2004, 
Hengeveld and Kersten 2015), and a proliferation-inducing ligand (APRIL) (Tai et al. 2016), RANK 
ligand (RANKL) (Schmiedel et al. 2013). 
Many have explored the tumor growth and drug resistance effects of NF-κB activation in MM, 
mediated by both the direct anti-apoptotic targets and the indirect signal inducer targets that further 
perpetuates the pro-survival signaling (Hideshima et al. 2007, Fairfield et al. 2016, Touzeau et al. 
2018). Consistently, therapeutic intervention for MM involves proteasome inhibitors that block IκB 
degradation and ultimately NF-κB signaling and immunomodulatory drugs that attenuates NF-κB 
autocrine and paracrine loops by acting on pro-inflammatory cytokines (Chim et al. 2018). 
Peripheral T cell lymphoma 
The NF-κB signaling in PTCL may be best characterized in adult T cell leukemia-lymphoma (ATL), 
a lymphoma caused by human T cell leukemia virus type 1 (HTLV-1) infection that occurs more 
frequently in HTLV-1–endemic areas such as southwestern Japan, the Caribbean Islands, Central 
and South America, intertropical Africa, and the Middle East (Iwanaga et al. 2012, Ishitsuka and 
Tamura 2014). Constitutive NF-κB activation in ATL (Mori et al. 1999) stems from various molecular 
mechanisms. In vitro and in vivo studies have demonstrated that the HTLV-1 Tax 34hosphor-
oncoprotein drives tumor development via NF-κB activation (Zhang et al. 2017a). Cell intrinsic 
mechanisms of NF-κB activation include NIK overexpression mediated by miR-31 silencing (Saitoh 
et al. 2008, Yamagishi et al. 2012) and mutations in genes involved in the lymphocyte antigen 
receptor-NF-κB axis such as PLCG1 (36%), PRKCB (33%; encoding PKCβ, a B cell counterpart of 
PKCθ), CARD11 (24%) and VAV1 (18%) (Kataoka et al. 2015). 
Other subtypes of PTCL have also shown evidence of NF-κB activation. Initial gene expression 
profiling and immunohistochemical (IHC) studies done in small scale or in cell line model to assess 
NF-κB activation status in PTCL have reported mixed results (Martinez-Delgado et al. 2004, 
Martinez-Delgado et al. 2005, Ballester et al. 2006, Piccaluga et al. 2007, Odqvist et al. 2013), but 
the more recent genetic, biochemical, and animal model studies demonstrate a more coherent 
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relationship between NF-κB activity and PTCL pathogenesis, especially in AITL and PTCL, NOS. 
A large-scale gene expression profiling study examining 144 lymphomas with broad representation 
of PTCL subtypes successfully delineated the biological subgroups, re-classified many PTCL, NOS 
cases based on the clustering, and reported a shared common signature of NF-κB enrichment in 
the AITL and PTCL, NOS cases that belong to the AITL subgroup (Iqbal et al. 2010). In addition, 
genomic sequencing studies, as discussed in the previous sections of the chapter (“Genetic and 
Molecular Landscape of PTCL”), have revealed diverse recurrent genomic abnormalities that lead 
to aberrant TCR and co-stimulatory signaling and in particular downstream NF-κB effector pathway 
in PTCL (Figure 1.2 and Table 1.2). Moreover, activated TCR or NF-κB signaling is described in 
all existing genetically manipulated murine models of AITL and PTCL, NOS (Pechloff et al. 2010, 
Wang et al. 2011, Beachy et al. 2012, Cortes et al. 2018, Mondragon et al. 2019, Kim and Cortés 
unpublished). In particular, PTCL development in T cell-conditional Nfkbia knockout mouse, whose 
lack of IκBα results in the constitutive NF-κB signaling, emphatically illustrates the capacity of NF-
κB activity to transform T cells (Mondragon et al. 2019). Despite these recent advances, however, 
the genetic and biochemical mechanism by which NF-κB is aberrantly activated as well as the 
oncogenicity of the NF-κB-activating genetic lesions in human PTCL remain unclear. 
Therapeutic targeting of NF-κB 
The crucial role of aberrant NF-κB activation in the pathogenesis of lymphoid malignancies 
presents a compelling rationale in support of therapeutic targeting of NF-κB in these diseases. 
Small molecule inhibitor that modulates NF-κB activity have achieved some success in clinics, 
including BTK inhibitor ibrutinib in ABC DLBCL (Wilson et al. 2015) and proteasome inhibitors 
bortezomib (Richardson et al. 2006), carfilzomib (Groen et al. 2019), and ixazomib (Richardson et 
al. 2018) in MM. Ibrutinib blocks BCR signaling and consequently BCR-mediated NF-κB activation 
(Young et al. 2015). Proteasome inhibitors prevent degradation of the canonical NF-κB inhibitor 
IκBα among many other proteins (Manasanch and Orlowski 2017). These pharmacologic inhibitors, 
however, do not selectively target the core components of the pathway and thus limited in their 
use. 
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Many have aggressively pursued IKK inhibition as one of the key druggable points in the NF-κB 
pathway (Karin et al. 2004). However, multiple drugs that appeared to have succeeded in preclinical 
models have failed in clinical trials due to either safety concerns or lack of efficacy resulting from 
dose-limiting toxicity of the global NF-κB blockade 
 (Prescott and Cook 2018).  
Some of the more promising NF-κB drug targets currently in development include other 
components of the IKK complex IKKα or NEMO, IκBα Degradation and NF-κB subunits (Begalli et 






III. Fyn Src family kinase 
 
 
Src family kinases (SFKs) are a group of non-receptor tyrosine kinases that include Src, Yes, Fyn, 
Fgr, Lck, Hck, Blk, Lyn, and Frk. In the 1970s, Mike Bishop and Harold Varmus isolated the gene 
encoding the first member of the family to be identified, SRC, and described its role in cancer 
development, defining what we now know as proto-oncogenes (Martin 2001). Multiple studies 
subsequently implicated SFKs in the development and maintenance of several cancers, including 
hematological malignancies (Zhang and Yu 2012, Ku et al. 2015). 
Among the nine Src family members, T cells throughout their lifespan primarily express Lck and 
Fyn. The two kinases serve specific and overlapping functional roles in T cell development and 
activation. This section will briefly discuss the structure and function of the Fyn kinase in the context 
of T cells. 
Domain structure of Fyn kinase 
Structural domains of Fyn are typical of SFKs: N-terminal Src-homology 4 (SH4) domain that 
contains attachment sites for saturated fatty acid addition, a “unique” domain particular to each 
member of the family, an SH3 and SH2 domain protein interaction domains, a tyrosine kinase 
domain SH1, and a C-terminal negative regulatory domain (Figure 1.8a). Post-translationally, the 
myristoylation of glycine 2 and the palmitoylation of cysteines 3 and 6 following the removal of the 
start methionine in SH4 domain anchor the kinase to the plasma membrane (Rawat and Nagaraj 
2010). Some studies in T cells have also indicated that Fyn interacts with the CD3 chain of the TCR 
complex, and in particular with ITAMs, via the SH4 domain (Timson Gauen et al. 1992, Timson 
Gauen et al. 1996, zur Hausen et al. 1997). The unique domain is the most divergent among the 
SFKs and likely to contribute substantially to the functional specificity of Lck and Fyn in T cells. The 
better characterized Lck unique domain, for example, contains a di-cysteine motif that mediates 
the kinase’s association with the CD4 and CD8 co-receptors (Turner et al. 1990, Kim et al. 2003). 
The SH3 and SH2 domains facilitate intra- and inter-molecular protein interactions and may confer 
adapter functions to the kinase in addition to its role as a tyrosine kinase (Zamoyska et al. 2003). 
Notably, even the SH1 kinase domain of Lck, the region that shows the most sequence homology 
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with Fyn (Figure 1.8a), does not fully share its function with the Fyn kinase domain (Lin et al. 2000). 
Not surprisingly given such difference, Fyn and Lck have overlapping but different sets of 
interacting partners (Table 1.6). 
 
 
Figure 1.8 – Fyn and Lck, Src family kinases. A, Domain structure of of Fyn (bottom) and Lck (top) kinases. 
Sequence homology and identity between the two related kinases are also indicated. b, Self-inhibitory 
mechanism of the Src family kinases. In the inactive or basal state, the kinase is in a closed conformation due 
to intramolecular binding of the SH2 domain with the phosphorylated tyrosine residue of the C-terminal 
regulatory region. Additionally, the SH3 domain interacts with a polyproline type II linker helix between the 
SH2 and SH1 domains to further lock the  inactive conformation. Upon dephosphorylation of the C-terminal 
tyrosine or binding of external ligands to SH2 or SH3 domains, the conformation changes to an open form that 
is regarded as the active state. Intermolecular autophosphorylation of tyrosine in the SH1 kinase domain 




Table 1.6 – Selected list of published Fyn and Lck interacting partners. Adapted from (Zamoyska et al. 
2003). 
Protein Binds to Published in 
CD3 Fyn 
(Samelson et al. 1990, Timson Gauen et al. 1992, Osman et al. 1996, Timson 
Gauen et al. 1996) 
Pyk2 Fyn (Qian et al. 1997) 
SAP/SLAM Fyn (Marie-Cardine et al. 1998) 
Shc Fyn (Wary et al. 1998) 
Gab-2 Fyn (Parravicini et al. 2002) 
WASp Fyn (Badour et al. 2004) 
Zap-70 Fyn, Lck (Duplay et al. 1994, Fusaki et al. 1996) 
PI3K Fyn, Lck (Thompson et al. 1992, Susa et al. 1996) 
c-Cbl Fyn, Lck (Tsygankov et al. 1996, Hawash et al. 2002) 
Sam68 Fyn, Lck (Fusaki et al. 1997) 
CD2 Fyn, Lck (Beyers et al. 1992) 
IL-2R Fyn, Lck (Hatakeyama et al. 1991, Kobayashi et al. 1993) 
Fas Fyn, Lck (Atkinson et al. 1996, Schlottmann et al. 1996) 
CD4/8 Lck (Turner et al. 1990, Kim et al. 2003) 
CD45 Lck (Schraven et al. 1991, Ng et al. 1996) 
MAPK Lck (August and Dupont 1996) 
RasGAP Lck (Amrein et al. 1992) 
Raf-1 Lck (Pathan et al. 1996) 
Lad Lck (Choi et al. 1999) 
 
Regulation of Fyn activation 
As in other SFKs, autoinhibitory mechanism regulates the activity of the Fyn kinase. In the inactive 
state, the phosphorylated Tyr 528 at the C-terminus negative regulatory region forms an 
intramolecular bond with the SH2 domain of the kinase, keeping the kinase in an inactive closed 
conformation. In addition to the Tyr 528 phosphorylation, mediated by C-terminal Src kinase (Csk), 
the SH3 domain of Fyn interacts with the polyproline type II linker helix between the SH2 and SH1 
domains to further lock the inactive conformation. Upon dephosphorylation of Tyr 528 by 
phosphatase CD45, the C-terminal of the kinase releases the SH2 domain to unmask the catalytic 
region of the protein and activate the kinase. Additionally, the kinase trans-phosphorylate each 
other at Tyr 417 to stabilize the active state (Figure 1.8b) (Salmond et al. 2009). 
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The role of Fyn in T cell development and function 
Mechanistically, Fyn along with Lck plays a crucial role in initiating the TCR signaling by 
phosphorylating and activating the cytoplasmic tail of the CD3 subunit in the receptor complex. For 
a more detailed overview of the proximal signaling following TCR activation, see section “NF-κB 
signaling in lymphoma – Overview of NF-κB signaling pathway – The Canonical Pathway.” In 
addition, mouse model studies have demonstrated the functional significance of Fyn in T cells. 
One of the major steps of the thymocyte development occurs following the TCR β chain 
rearrangement to select for only the cells that express functional β chains. In this process, called 
the β selection, cells cannot survive without signaling triggered via pre-TCR, a signaling complex 
formed by the β chain and pre-TCRα. 
The complete lack of cells that pass the β selection in the double knockout Lck-/- Fyn-/- mice 
indicates the crucial role of these SFKs in T cell development (Groves et al. 1996, van Oers et al. 
1996). In single knockout mouse models, Fyn-/- mice are normal in numbers and proportions of 
thymocytes (Appleby et al. 1992, Stein et al. 1992), in contrast to Lck deficient mice, which show 
about 90% reduction in the number of thymocytes that survive the β selection (Molina et al. 1992). 
Similarly, Lck-deficient mouse T cells have a 10-fold decreased proliferative response after CD3 
stimulation (Molina et al. 1992), whereas Fyn-deficient mouse T cells show only mild impairment 
apart from the dramatic reduction in IL-2 production (Appleby et al. 1992, Stein et al. 1992). These 
mouse models suggest that while both Lck and Fyn play important roles in T cell development and 
activation, Fyn function appears to overlap significantly with the role of Lck.  
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IV. NF-κB activating signal transducer, TRAF3IP2 
 
 
TRAF3IP2 encodes the NF-κB activating signal transducer TRAF3IP2, also known as Act1 or CIKS, 
which belongs to the similar expression of fibroblast growth factor/ interleukin-17 receptor (SEFIR) 
domain protein family. SEFIR is a homotypic protein interaction domain that is distantly related to 
the toll/interleukin-1 receptor (TIR) homology domain of toll-like receptors (TLRs), interleukin-1 
receptor (IL-1R), and their adaptor proteins such as Myd88 (Novatchkova et al. 2003). The only 
member of the SEFIR family identified besides the interleukin-17 (IL-17) receptors, TRAF3IP2 
binds to the SEFIR domain of IL-17Rs and serves an essential role in all known IL-17-dependent 
signaling pathways, most prominently NF-κB activation (Gu et al. 2013). Of note, structure studies 
have shown that TRAF3IP2 can also homo-oligomerize via the SEFIR domain (Mauro et al. 2003, 
Zhang et al. 2013). 
IL-17 promotes inflammatory response either by transcriptional activation of the proinflammatory 
genes or by stabilization of target mRNA transcripts. As hematopoietic cells largely lack expression 
of IL-17 receptor C (IL-17RC), an essential subunit of the predominant form of the IL-17R complex, 
the response to IL-17 primarily arise from non-hematopoietic cells (Ho et al. 2010, Amatya et al. 
2017). 
IL-17R signaling is analogous to IL-1R/TLR pathways in that the proximal signal transduction 
occurs via homotypic protein-binding domain interaction between the receptor and the adaptor 
protein. Upon receptor ligation, TRAF3IP2 via its C-terminal SEFIR domain (Figure 1.9) binds to 
the IL-17R complex. In addition to its role as an adaptor that links the receptor signal and the 
effector tumor necrosis factor receptor (TNFR)-associated factor (TRAF) proteins, TRAF3IP2 also 
serves as a K63 E3 ubiquitin ligase via the U-box domain (Liu et al. 2009) (Figure 1.9). TRAF3IP2 
recruits another K63 E3 ligase TRAF6 via the N-terminal TRAF-binding motif (Ryzhakov et al. 2011, 
Sonder et al. 2011) and together initiates a poly-ubiquitinated scaffold that brings TAK1 and IKK 
complex to ultimately activate the canonical NF-κB signaling (Figure 1.10) (see section “NF-κB 
signaling in lymphoma – Overview of NF-κB signaling pathway – The Canonical Pathway” for 
details on the role of protein oligomerization, ubiquitination, and IKK recruitment in the canonical 
NF-κB activation). In addition to NF-κB activation, TRAF3IP2 also participates in mitogen-activated 
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protein kinase (MAPK) pathways and TRAF2 and TRAF5-mediated stabilization of target gene 
mRNAs (Amatya et al. 2017) (Figure 1.10). NF-κB activation, however, is the most prominent event 
downstream of TRAF3IP2, as evidenced by the overrepresentation of NF-κB promoter elements in 
IL-17 target genes (Shen et al. 2006). 
 
 
Figure 1.9 – Domain structure of TRAF3IP2. HLH, Helix-loop-helix domain; SEFIR, similar expression of 
fibroblast growth factor/ interleukin-17R (SEFIR) domain. The amino acid sequence and the location of the 





Figure 1.10 – Activation of IL-17 Signal Transduction. Receptor ligation enables homotypic interactions 
between the SEFIR domains in the receptor and in TRAF3IP2. TRAF3IP2-induced K63-linked ubiquitination 
of TRAF6 activates the MAPK, C/EBPβ and NF-κB pathways, triggering transcriptional activation of 
downstream target genes, including pro-inflammatory cytokines, chemokines and antimicrobial peptides. 
Additionally, TRAF3IP2, when phosphorylated at amino acid 311, recruits TRAF2 and TRAF5 to stabilize 
mRNA transcripts of certain target genes. Adapted from (Monin and Gaffen 2018). 
 
Unexpectedly, in B cells that lack the classical IL-17 receptor, TRAF3IP2 serves as a negative 
regulator of BAFF and CD40 signaling (Qian et al. 2004). While the mechanism is not entirely clear, 
protein interaction studies seem to indicate that TRAF3IP2 suppresses the signaling by recruiting 
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TRAF3 (Qian et al. 2004). Given the role of TRAF3 in NIK activity (see section “NF-κB signaling in 
lymphoma – Overview of NF-κB signaling pathway – The Alternative Pathway”), TRAF3IP2 may 
negatively mediate the alternative NF-κB signaling and positively regulate the canonical pathway 
depending on the context. 
Given the significant role that TRAF3IP2 plays in NF-κB activation and inflammation, TRAF3IP2 is 
implicated in various inflammatory diseases, including psoriasis (Hobbs et al. 2017), candidiasis 




V. Specific Aims 
 
 
Peripheral T cell lymphomas (PTCL) are highly aggressive lymphoid tumors derived from post-
thymic mature T cells. Angioimmunoblastic T cell lymphoma (AITL) and PTCL, not otherwise 
specified (PTCL, NOS) account for about half of the cases and show poor outcomes under current 
therapeutic options. Despite major advances in the understanding of PTCL tumor biology over the 
past few years, AITL and PTCL, NOS still lack clear actionable targets. Therefore, discovering new 
oncogenic drivers and defining their mechanism of action are major research imperatives in AITL 
and PTCL, NOS. 
Previous exome sequencing studies have revealed a diverse set of point mutations, indels, and 
copy number changes in AITL and PTCL, NOS, but reports of gene fusions have been scarce. 
Considering the important role that chromosomal rearrangements play in the pathogenesis and 
clinical management of other hematologic malignancies, my central hypothesis is that gene fusions 
induce oncogenesis in AITL and PTCL, NOS by aberrantly activating a specific pathway that is 
central to the pathogenesis of the disease. In that context, identification and characterization of 
fusion oncogene in AITL and PTCL, NOS will enable us to better understand the disease and 
facilitate the development of effective therapeutics. Thus, the central goal of this thesis was to 
identify and functionally characterize fusion genetic drivers of T cell transformation in AITL and 
PTCL, NOS. Towards this goal, I proposed the following aims: 
 
Aim 1: To identify recurrent fusion genes in AITL and PTCL, NOS. 
Aim 2: To functionally characterize the role of novel fusion genes in T cell transformation 
in vitro and in vivo. 
Aim 3: To therapeutically target the downstream effector pathogenic mechanism of PTCL 
fusion oncogenes.  
 45 
Chapter 2: Identification of a FYN-TRAF3IP2 gene fusion in PTCL 
 
 
With the goal of identifying new therapeutic targets in PTCL, we investigated the presence of new 
recurrent gene fusion events in RNAseq data from a cohort of 101 PTCL samples consisting of 
AITL (n=60) and PTCL, NOS (n=41) cases (Abate et al. 2017). These analyses identified the 
presence of chimeric reads spanning exon 8 of FYN and exon 3 of TRAF3IP2 in two AITL cases 
supporting expression of a new recurrent FYN-TRAF3IP2 fusion joining the FYN non-receptor 
tyrosine kinase gene (Palacios and Weiss 2004) and TRAF3IP2, which encodes a cytoplasmic 
adapter signaling protein downstream of the interleukin 17 receptor (IL17R) (Li et al. 2000, Chang 
et al. 2006, Qian et al. 2007) (Figure 2.1a and Table 2.1). 
 
Table 2.1 – Chimeric FYN-TRAF3IP2 RNAseq reads. 
Sample Diagnosis FYN breakpoint TRAF3IP2 breakpoint Reads Split reads 
TP47 AITL 111,702,885 111,592,094 37 29 
TP58 AITL 111,702,885 111,592,094 11 9 
 
Reverse-transcription PCR (RT-PCR) amplification and dideoxynucleotide sequencing validated 
the expression of the FYN-TRAF3IP2 fusion mRNAs in each of these index samples (Figure 2.1b). 
In addition, extended analysis by RT-PCR and sequencing of an independent panel of PTCL RNA 
samples with broad representation of PTCL subtypes (Table 2.2) revealed the presence of FYN-
TRAF3IP2 fusion transcripts in 8/28 cases (28%), which included 4/9 (44%) AITLs, 3/6 (50%) 




Figure 2.1 – Identification of the FYN-TRAF3IP2 gene fusion in PTCL. A, Schematic representation of the 
FYN-TRAF3IP2 fusion transcripts identified in RNAseq. Each horizontal line represents a chimeric FYN-
TRAF3IP2 RNAseq read. B, Representative dideoxynucleotide sequencing result of the FYN-TRAF3IP2 
cDNA from a PTCL index sample. C, Frequency and distribution across PTCL groups of samples harboring 
the FYN-TRAF3IP2 fusion transcript (total, n=28; AITL, n=9; PTCL, NOS, n=6; Extranodal NKTCL, nasal type, 
n=1; ALCL, n=2; HSTCL, n=3; CTCL, n=3; ATL, n=1; SPTCL, n=1). D, Schematic representation of the 
chromosomal rearrangement event resulting in expression of the FYN-TRAF3IP2 fusion RNA and breakpoint 
sequence identified by whole genome sequencing. E, Schematic representation of the structures of the FYN 
kinase, TRAF3IP2 protein, and FYN-TRAF3IP2 fusion protein. SH3, Src homology 3 domain; SH2, Src 
homology 2 domain; TBM, TRAF-binding motif; HLH, Helix-loop-helix domain; SEFIR, SEF/IL-17R signaling 
domain. 
 47 




Tissue Site Reduced Diagnosis Fusion 
1 40% Lymph Node, Left Axillar AITL  
2 30% 
Lymph Node, Left Posterior 
Cervical 
AITL  
4 30% Lymph Node, Right Neck PTCL, NOS TFH yes 
5 50% Spleen HSTCL  
6 40% Lymph Node, Right Level 4 AITL, recurrent yes 
7 15% Spleen PTCL, NOS yes 
8 70% Lymph Node, Neck Level 2 ATL  
9 40% Lymph Node, Right Axillary PTCL, NOS, recurrent  
10 50% 
Lymph Node, Neck Left Deep 
Cervical 
PTCL, NOS Lennert-like  
11 25% 
Mediastinum and Lymph Node, 
Supraclavicular 
ALK+ ALCL  
12 25% Lymph Node, Right Inguinal AITL  
13 30% Abdomen, Abdominal Wall SPTCL  
14 20% Lymph Node, Right Groin AITL  
15 25% Lymph Node, Left Axillary AITL  
16 40% Lymph Node, Left Groin PTCL, NOS TFH, recurrent yes 
17 70% Lymph Node, Left Axilla CTCL  
18 20% 
Lymph Node, Left 
Supraclavicular 
ALK+ ALCL  
19 25% Spleen HSTCL  
22 30% Lymph Node, Left Axillary CTCL  
23 70% Testis, Right ENKTCL, nasal type yes 
24 20% Lymph Node, Left Axillar AITL yes 
25 50% Spleen HSTCL  
28 50% Lymph Node, left inguinal ALK- ALCL  
30 40% Lymph Node, left iliac PTCL, NOS TFH  
32 5% Lymph Node, right groin CTCL  
33 20% Lymph Node, left axillary  AITL yes 
34 15% Lymph Node, left neck AITL yes 
35 15% 
Lymph nodes, anterior 
mediastinal and right 
paratracheal 
ALK- ALCL  
 
AITL, angioimmunoblastic T cell lymphoma; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma 
kinase; ATL, adult T cell lymphoma; CTCL, cutaneous T cell lymphoma; ENKTCL, extranodal NK/T cell 
lymphoma; HSTCL, hepatosplenic T cell lymphoma; PTCL, NOS, peripheral T cell lymphoma, not otherwise 





Figure 2.2 – FYN-TRAF3IP2 detection by RT-PCR and dideoxynucleotide sequencing. A, Reverse-
transcription PCR (RT-PCR) amplification results of an independent panel of 28 PTCL RNA samples spanning 
the region of FYN-TRAF3IP2 fusion breakpoint. B, DNA sequencing chromatograms of the RT-PCR 
amplicons generated in a. 
 
 
Structurally, FYN and TRAF3IP2 are adjacently located loci in head to tail orientation with the 
TRAF3IP2 gene positioned 53.4 kb centromeric from FYN in the long arm of chromosome 6 (Figure 
2.1d). To investigate the mechanism underlying the expression of FYN-TRAF3IP2 fusion mRNAs 
in PTCL, we performed deep (100x) whole genome sequencing of a FYN-TRAF3IP2-expressing 
AITL sample with available genomic DNA.  Analysis of structural abnormalities identified a 
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chromosome 6 rearrangement joining FYN intron 8 (Chr6:111,702,370) and TRAF3IP2 intron 2 
(Chr6:111,592,704) (Figure 2.1d and Table 2.3). This genetic alteration spanning 109,666 base 
pairs generates a gene fusion predicted to express a FYN-TRAF3IP2 chimeric RNA with FYN 
exons 1-8 splicing into exon 3 of TRAF3IP2, in concordance with the results of RNAseq analyses 
in this sample.  
 
 
Table 2.3 – Genomic breakpoint of FYN-TRAF3IP2 fusion analyzed by whole genome sequencing. 
Sample Diagnosis FYN breakpoint TRAF3IP2 breakpoint Reads Split reads 
TP58 AITL 111,702,370 111,592,704 2 2 
 
 
Table 2.4 – Mutational profile of FYN-TRAF3IP2 harboring sample analyzed by whole genome 
sequencing. 
Sample Chr Position Ref Var Gene AA Transcript ID 
Variant 
Frequency 
TP58 3 49412973 C A RHOA G17V NM_001664 13 
TP58 4 105236364 G T TET2 E808* NM_001127208 14 
TP58 7 2928644 T G CARD11 N570H NM_032415 9 
TP58 7 2928646 C A CARD11 G569V NM_032415 5 
TP58 20 41162516 T G PLCG1 F193V NM_182811 8 
TP58 20 41163397# G A PLCG1 R270H NM_182811 54 
TP58 20 41163423# A G PLCG1 S279G NM_182811 54 
TP58 20 41168825# T C PLCG1 I813T NM_182811 100 
 
Chr, chromosome number; Ref, reference; Var, variant; AA, amino acid change. 
* stop gain. # germline single nucleotide polymorphism. 
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Chapter 3: Functional characterization of FYN-TRAF3IP2 
 
 
The chimeric protein encoded by FYN-TRAF3IP2 contains the N-terminal membrane localization 
motif and the SH3 and SH2 domains (aa1-232) of FYN, but not its SH1 kinase domain, in fusion 
with all known motifs and domains of TRAF3IP2 (aa7-574) including its helix-loop-helix domain, a 
TRAF6-ubiquitinating U-Box domain, three putative TRAF-binding motifs and its IL-17R-
associating SEFIR domain (Figure 2.1e). Mechanistically, this protein configuration suggests that 
FYN-TRAF3IP2 could result in aberrant TRAF3IP2-mediated signaling rather than inducing 
oncogenic FYN kinase activity.  
The TRAF3IP2 adaptor protein plays an important role in mediating NF-κB signaling downstream 
of the IL17 receptor(Li et al. 2000, Chang et al. 2006, Qian et al. 2007). However, IL17R is not 
functionally expressed in T cells (Figure 3.1a) (Kuestner et al. 2007, Gaffen 2009, Ishigame et al. 
2009). Consistently, IL17 treatment failed to elicit increased NF-κB signaling in GFP NF-κB reporter 
Jurkat T cells infected with empty vector, wild type TRAF3IP2 and FYN-TRAF3IP2 expressing 
lentiviruses (Figure 3.1b).   
 
 
Figure 3.1 – T cells do not functionally express IL17 receptors. A, RNA expression level of IL17RC, 
essential for a functional IL17 receptor (Ho et al. 2010), in T cells and monocytes represented from DICE 
(Database of Immune Cell Expression, Expression quantitative trait loci and Epigenomics). B, NF-κB-GFP 
reporter activity in transduced Jurkat cells after stimulation with 200 ng/mL IL17A. Results are reported as 
mean of triplicate values (bar) ± standard deviation (error bar) with individual values (white circles). P values 
were calculated using two-tailed Student’s t-test. 
 
In this context, and given the prominent role of TCR signaling as driver of PTCL proliferation and 
survival (Wilcox 2016), we proposed an aberrant adaptor role for FYN-TRAF3IP2 linking TCR 
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activation to NF-κB signaling. In agreement with this hypothesis, TCR stimulation of FYN-
TRAF3IP2-expressing Jurkat cells with an anti-CD3 antibody led to significantly increased NF-κB 
reporter activity compared with controls (Figure 3.2b). Similarly, treatment with phorbol 12-
myristate 13-acetate (PMA), which mimics the effects of diacylglycerol, a second messenger 
inducing protein kinase C (PKC) activation downstream of TCR signaling, induced markedly 
increased NF-κB reporter responses in FYN-TRAF3IP2-expressing Jurkat cells compared with wild 
type TRAF3IP2 expressing and empty vector infected controls (Figure 3.2c). In all, these results 
support a role for FYN-TRAF3IP2 as a driver of NF-κB activation downstream of TCR-induced PKC 
signaling in PTCL. 
  
 
Figure 3.2 – FYN-TRAF3IP2 drives NF-κB activation in response to TCR-induced PKC signaling. a, 
Immunoblot analysis of Jurkat NF-κB-GFP reporter cells lentivirally transduced with empty vector or with 
viruses driving expression of wild type TRAF3IP2-V5 or the FYN-TRAF3IP2-V5 fusion. IB, immunoblot. B, NF-
κB-GFP reporter activity in Jurkat cells as in a after stimulation with anti-CD3 (a-CD3) antibody.  C, NF-κB-
GFP reporter activity in Jurkat cells as in a after treatment with increasing doses of PMA.  Bar graphs indicate 
the mean of triplicate values. Error bars indicate ± standard deviation. Individual values are shown as white 
circles. P values were calculated using two-tailed Student’s t-test. 
 
Recruitment of adaptor and signaling factors to multiprotein complexes in the plasma membrane 
plays an important role in TCR signal transduction (Chakraborty and Weiss 2014). The FYN N-
terminal sequence GCVQCKDK is myristoylated (at the Gly site) and palmitoylated (at the two Cys 
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sites) and targets localization of the FYN protein to the plasma membrane (Wolven et al. 1997, 
Sato et al. 2009) (Figure 3.3a). The presence of this motif in FYN-TRAF3IP2 supports a potential 
role for aberrant membrane recruitment of this fusion protein in NF-κB activation. Subcellular 
fractionation analyses of cells expressing TRAF3IP2 or the FYN-TRAF3IP2 fusion recovered FYN-
TRAF3IP2 in the membrane fraction, while wild type TRAF3IP2 was primarily located in the cytosol 
(Figure 3.3b). Moreover, mutation (ASVQSKDK) of the FYN-TRAF3IP2 FYN membrane 
localization motif (Wolven et al. 1997) (Figure 3.3a) resulted in delocalization of this fusion protein 
to the cytosolic compartment (Figure 3.3b). Consistently, immunofluorescence analysis of C-
terminal 3xFlag-tagged proteins showed plasma membrane localization of FYN-TRAF3IP2 and a 
diffuse cytosolic localization pattern for wild type TRAF3IP2 and ASVQSKDK FYN-TRAF3IP2 
(Figure 3.3c). Moreover, and in support of a mechanistic functional role of plasma membrane 
localization in FYN-TRAF3IP2-mediated signaling, introduction of the ASVQSKDK membrane 
localization motif mutation in FYN-TRAF3IP2 abrogated the capacity of this fusion protein to 
activate NF-κB in reporter assays (Figure 3.3d).  
Activation of NF-κB downstream of PKCθ after TCR activation involves the assembly of a 
multiprotein complex containing CARD11, BCL10 and MALT1 (CBM signalosome) (Meininger and 
Krappmann 2016), which upon activation, recruits and activates TRAF6. This, in turn, triggers 
multiple K63-linked (TRAF6 and BCL10-mediated) and M1-linear (linear ubiquitin chain assembly 
complex (LUBAC)-mediated) ubiquitination events, which collectively mediate phosphorylation and 
activation of the IKK complex (Meininger and Krappmann 2016) leading to degradation of the IκBα 
NF-κB inhibitory factor, leading to NF-κB nuclear localization and consequently, to activation of NF-




Figure 3.3 – Membrane localization of FYN-TRAF3IP2. A, Schematic representation of the FYN-TRAF3IP2 
fusion protein indicating the wild type and mutant membrane localization motif sequences. B, Immunoblot 
analysis (left) and quantification (right) of cytosolic and membrane-associated FLAG-tagged proteins after 
subcellular fractionation in Jurkat cells expressing wild type TRAF3IP-3xFLAG, FYN-TRAF3IP2-3xFLAG, or 
membrane localization mutant ASVQSKDK FYN-TRAF3IP2-3xFLAG. C, Immunofluorescence analysis of 
cellular localization of FLAG-tagged proteins in HeLa cells expressing wild type TRAF3IP2-3xFLAG, FYN-
TRAF3IP2-3xFLAG, and membrane localization mutant ASVQSKDK FYN-TRAF3IP2-3xFLAG. FLAG-tagged 
proteins are shown in red, the Na/K ATPase membrane marker in green, and DAPI-stained nuclei in blue. 
Scale bar = 20 μm. D, NF-κB dual luciferase reporter activity (right) and immunoblot analysis (left) of 293T 
cells transduced with empty vector or lentivirus driving expression of wild type TRAF3IP2-V5, FYN-TRAF3IP2-
V5, or mutant ASVQSKDK FYN-TRAF3IP2-V5. Bar graphs indicate the mean of triplicate values. Error bars 
indicate ± standard deviation. Individual values are shown as white circles. P values were calculated using 
two-tailed Student’s t-test. IB, immunoblot. 
 
To test if FYN-TRAF3IP2 could activate NF-κB via the CBM complex, we analyzed the ability of 
PKC activation induced by PMA treatment to trigger expression of a NF-κB-GFP reporter in wild 
type and CARD11 knockout Jurkat cells (Wang et al. 2002) (Figure 3.4) expressing FYN-
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TRAF3IP2. In these experiments, empty vector control and wild type TRAF3IP2-expressing 
CARD11 deficient cells showed a marked impairment in NF-κB signaling triggered by PMA 
treatment, which was effectively rescued by lentiviral expression of CARD11-HA (Figure 3.5a,b). 
In contrast, CARD11 knockout Jurkat cells expressing FYN-TRAF3IP2 readily activated the NF-
κB-GFP reporter in response to PMA treatment (Figure 3.5a,b). This result demonstrates a CBM-
independent role for FYN-TRAF3IP2 as mediator of TCR-induced NF-κB activation in PTCL. 
 
 
Figure 3.4 – Knock out and reconstitution of CARD11 in Jurkat cells. Immunoblot analysis a and NF-κB-
GFP reporter activity after stimulation with 25 nM of PMA or 20 ng/mL TNFα b of JPM50.6 CARD11 knockout 
and JPM50.6 cells reconstituted by CARD11-HA expression. Results are reported as mean of triplicate values 
(bar) ± standard deviation (error bar) with individual values (white circles). P values were calculated using two-
tailed Student’s t-test. 
 
Interestingly, both IL17R signaling and TCR-CBM signalosome NF-κB activation engage TRAF6, 
a ubiquitin ligase prominently involved in NF-κB signaling upstream of IKKβ activation (Walsh et al. 
2015). Moreover, TRAF6 can directly interact with TRAF3IP2, via association with TRAF-binding 
motifs present in the FYN-TRAF3IP2 fusion protein (Liu et al. 2009, Ryzhakov et al. 2011, Sonder 
et al. 2011), suggesting a potential role for TRAF6 in FYN-TRAF3IP2-mediated NF-κB activation. 
Consistent with this possibility, immunoprecipitation and western blot analyses demonstrated that, 
similar to wild type TRAF3IP2, the FYN-TRAF3IP2 protein can prominently interact with TRAF6 
(Figure 3.5d). Moreover, introduction of a disruptive focal mutation (PVAVAA) (Ryzhakov et al. 
2011) in the TRAF3IP2 TRAF6-binding motif of FYN-TRAF3IP2 (Figure 3.5c) impaired the ability 
of this fusion protein to interact with TRAF6 (Figure 3.5d) and its capacity to respond to PMA in 
Jurkat NF-κB-GFP reporter assays (Figure 3.5e). 
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Figure 3.5 – FYN-TRAF3IP2 engages TRAF6 to activate CARD11-independent NF-κB signaling. a, 
Immunoblot analysis of CARD11 knockout Jurkat cells and CARD11-HA reconstituted CARD11 knockout cells 
infected with empty vector or lentiviruses driving expression of TRAF3IP2-V5 or the FYN-TRAF3IP2-V5 fusion. 
b, NF-κB-GFP reporter activity after stimulation with 25 nM PMA in Jurkat cells as in a. c, Schematic 
representation of the FYN-TRAF3IP2 fusion protein indicating the wild type and mutant TRAF6-binding motif. 
d, Micrograph (top) and quantification (bottom) of IP western analyzing the interaction between HA-TRAF6 
and V5-tagged proteins in 293T cells expressing wild type TRAF3IP2-V5, FYN-TRAF3IP2-V5 or PVAVAA 
FYN-TRAF3IP2-V5 or in the empty vector control. e, Immunoblot analysis of Jurkat cells transduced with 
empty vector or lentivirus driving expression of wild type TRAF3IP2-V5, fusion FYN-TRAF3IP2-V5, or mutant 
PVAVAA FYN-TRAF3IP2-V5 (top) and corresponding NF-κB-GFP reporter activity (bottom) after stimulation 
with 25nM PMA. IP, immunoprecipitation; IB, immunoblot. Bar graphs in a and e indicate the mean of triplicate 
values. Error bars indicate ± standard deviation. Individual values are shown as white circles. P values were 
calculated using two-tailed Student’s t-test. Bar graphs in d indicate protein interaction levels normalized to 
TRAF3IP2-V5. 
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Collectively, these results suggest a mechanism in which localization of FYN-TRAF3IP2 at the 
membrane rewires the TCR signal transduction pathway resulting in enhanced and dysregulated 
NF-κB signaling. Analogous to the CBM signaling, NF-κB activation by FYN-TRAF3IP2 also 
responds to TCR and PKC activation, but redirects this input signal to directly recruit TRAF6 and 
activate NF-κB circumventing the CBM complex (Figure 3.6). 
 
 
Figure 3.6 – Schematic representation FYN-TRAF3IP2 signaling in T cells. The T cell receptor 
downstream second messenger diacylglycerol activates and recruits PKC to the plasma membrane. In 
physiologic T cells, CARD11, upon phosphorylation by PKC, nucleates the CARD11-BCL10-MALT1 (CBM) 
complex, which involves several factors including TRAF6 to form a polyubiquitinated signaling platform to 
activate the classical IKK complex. The activated IKK complex subsequently catalyzes IκBα phosphorylation, 
which triggers K48-linked polyubiquitination of the substrate followed by proteasomal degradation. Relieved 
from the inhibitory protein, NF-κB transcription factors then accumulate in the nucleus and activate target 
genes. Analogous to the physiologic signaling, NF-κB activation by FYN-TRAF3IP2 also responds to TCR and 
PKC activation. Localization of FYN-TRAF3IP2 at the membrane rewires the TCR signal transduction pathway 
by redirecting the input TCR signals to circumvent the CBM complex and directly recruit TRAF6, resulting in 
enhanced and dysregulated NF-κB signaling.  
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Chapter 4: Oncogenic role of FYN-TRAF3IP2 in PTCL 
 
 
Loss-of-function TET2 mutations are highly recurrent genetic lesions in PTCL (Couronne et al. 
2012, Lemonnier et al. 2012, Palomero et al. 2014, Sakata-Yanagimoto et al. 2014), can be found 
in association with FYN-TRAF3IP2 (Table 2.4), and accelerate the development of PTCL in mice 
(Cortes et al. 2018). To investigate the oncogenic activity of FYN-TRAF3IP2 we analyzed the 
lymphomagenic effects of expressing this gene fusion alone and in cooperation with loss of the 
Tet2 tumor suppressor gene in vivo. In these experiments, we first infected hematopoietic 
progenitors from CD4-specific tamoxifen-inducible Cre Tet2 conditional knockout mice (CD4 Cre-
ERT2, Tet2fl/fl) with bicistronic retroviruses expressing wild type TRAF3IP2 and GFP, FYN-
TRAF3IP2 and GFP, or GFP alone and injected these intravenously into isogenic recipients (Figure 
4.1) Transplanted mice were then treated with vehicle only, to test the oncogenic effects of 
TRAF3IP2, FYN-TRAF3IP2 or GFP expression; or with tamoxifen, to evaluate the effects of 
TRAF3IP2, FYN-TRAF3IP2 or GFP expression in concert with genetic loss of Tet2 in CD4 T cells.  
In this setting, all animals transplanted with GFP-expressing progenitors remained lymphoma free 
at the end of follow up and one animal transplanted with wild type TRAF3IP2 GFP expressing cells 
developed a CD8+ T cell lymphoma (Figure 4.2a,b). In contrast, and most notably, 4/10 (40%) 
vehicle treated mice transplanted with FYN-TRAF3IP2-expressing cells developed clonal CD4-
restricted mature T cell lymphomas with a latency of 28 weeks in support of a driver oncogenic role 
for FYN-TRAF3IP2 in PTCL (Figure 4.2a). In addition, mice transplanted with FYN-TRAF3IP2-
expressing progenitors and treated with tamoxifen to delete Tet2 in the CD4 T cell compartment 
showed accelerated mortality with a latency of 22 weeks, supporting a cooperative role between 
Tet2 loss and FYN-TRAF3IP2 in lymphoma development. By 44 weeks post-transplant, 7/10 of 
mice in this group were euthanized with signs of disease (Figure 4.2c). Of these, 5/7 were 
diagnosed with CD4-positive T cell lymphoma based on histopathological and flow cytometry 




Figure 4.1 – Schematic representation of bone marrow transplant experiment analyzing the 
lymphomagenic activity of FYN-TRAF3IP2. We transduced hematopoietic progenitors from CD4 Cre-ERT2 
Tet2fl/fl mice with bicistronic retroviruses driving the expression of GFP, FYN-TRAF3IP2-V5 and GFP or wild 
type TRAF3IP2-V5 and GFP. We intravenously transplanted the infected cells into lethally irradiated C57BL/6 
recipient mice and treated them 8 weeks post-transplant with vehicle only or with tamoxifen to preserve or 
delete Tet2 in CD4+ T cells, respectively. These cohorts of mice were then immunized with sheep red blood 
cells every 4-5 weeks to induce peripheral T cell activation. 
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Figure 4.2 – Expression of FYN-TRAF3IP2 in mouse hematopoietic progenitors induces PTCL, NOS. 
a, Kaplan-Meier survival curves of mice transplanted with bone marrow progenitor cells from CD4 Cre-ERT2 
Tet2fl/fl mice retrovirally transduced to express GFP only, wild type TRAF3IP2 and GFP, or fusion FYN-
TRAF3IP2 and GFP treated with vehicle (blue arrow) 8 weeks post-transplant. b, Splenic weight of animals at 
the endpoint after transplantation as in a. Red circles, GFP+ CD4+ lymphoma; black circles, no lymphoma; 
gray circle, GFP+ CD8+ lymphoma; horizontal line, mean value. P values were calculated using two-tailed 
Student’s t-test. c, Kaplan-Meier survival curves of mice transplanted with bone marrow progenitor cells from 
CD4 Cre-ERT2 Tet2fl/fl mice retrovirally transduced to express GFP only, wild type TRAF3IP2 and GFP, or 
fusion FYN-TRAF3IP2 and GFP treated with tamoxifen (red arrow) 8 weeks post-transplant. d, Splenic weight 
of animals at the endpoint after transplantation as in c. Red circles, GFP+ CD4+ lymphoma; black circles, no 
lymphoma; horizontal line, mean value. P values were calculated using two-tailed Student’s t-test. e, 
Histological micrographs of hematoxylin-eosin stained spleen sections of immunized control mice and FYN-
TRAF3IP2-induced CD4+ PTCL, NOS. Scale bar = 400 μm.  f, Representative FACS plot showing GFP+ CD4+ 
lymphoma cells in lymphoma-infiltrated spleens from FYN-TRAF3IP2 diseased mice. g, Immunoblot analysis 
of FYN-TRAF3IP2-V5 protein expression in control splenocytes and in the lymphoma-infiltrated spleen of a 
FYN-TRAF3IP2 diseased mouse. h, Tcr Vβ clonality in FYN-TRAF3IP2 lymphoma cells (GFP+ CD4+) and 
normal CD4 T cells  (GFP- CD4+) from a diseased mouse. i, Tcrb clonal distribution in FYN-TRAF3IP2-induced 
CD4+ primary tumors and in a representative allografted secondary lymphoma. Sectors represent the fraction 
of reads corresponding to individual Tcrb sequences. 
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Mice harboring FYN-TRAF3IP2-induced lymphomas showed splenomegaly and generalized 
lymphadenopathy (Figure 4.2b,d and Figure 4.3a,b). Histopathological examination of enlarged 
lymph nodes and spleen showed replacement of lymphoid follicles with a diffuse pleomorphic 
lymphohistiocytic infiltrate composed predominantly of atypical lymphocytes (Figure 4.2e). Flow 
cytometry analysis of splenocytes in lymphoma bearing mice demonstrated the presence of GFP+ 
cells derived from FYN-TRAF3IP2 GFP infected progenitors (Figure 4.2f) and immunoblot analysis 
verified the expression of the FYN-TRAF3IP2 protein (Figure 4.2g). In addition, histological and 
flow cytometry analyses of extranodal sites revealed infiltration of the bone marrow and peripheral 
tissues including liver, kidneys and lungs by GFP+ tumor cells indicating disseminated disease 
(Figure 4.3c-e). GFP+ tumor cells in FYN-TRAF3IP2-induced lymphoma showed a CD4+ 
immunophenotype (Figure 4.2f). In addition, analyses of TFH markers showed upregulation of 
ICOS and PD1, but variable and generally limited expression of CXCR5 and BCL6 (Figure 4.4b,c 
and Table 4.1). Moreover, sequencing and flow cytometry analyses of the TCR repertoire of FYN-
TRAF3IP2 lymphoma cells revealed clonal expansion of T cell populations (Figure 4.2h,i). Finally, 
transplantation of splenic cells from diseased mice into secondary recipients led to accelerated 
development of secondary lymphomas (Figure 4.5a), which retained the histological and 
immunophenotypic features of the primary tumor (Figure 4.5b-e) with increased T cell clonality 
(Figure 4.2 and Figure 4.5f). 
 
Table 4.1 – TFH marker expression in mouse FYN-TRAF3IP2 PTCL, NOS 
Sample ID Genotype CD4 PD1 CXCR5 ICOS BCL6 
Lymphoma_1 Tet2-/- FYN-TRAF3IP2 o o x o x 
Lymphoma_2 Tet2-/- FYN-TRAF3IP2 o o x o x 
Lymphoma_3 Tet2-/- FYN-TRAF3IP2 o o x o o 
Lymphoma_4 Tet2-/- FYN-TRAF3IP2 o o o o x 
Lymphoma_5 Tet2-/- FYN-TRAF3IP2 o o x o x 
Lymphoma_6 Tet2fl/fl FYN-TRAF3IP2 o o x o x 
Lymphoma_7 Tet2fl/fl FYN-TRAF3IP2 o o x o x 
Lymphoma_8 Tet2fl/fl FYN-TRAF3IP2 o o x o x 





Figure 4.3 – FYN-TRAF3IP2-induced lymphomas infiltrate lymphoid organs, bone marrow and solid 
tissues in mice. a, Spleens from FYN-TRAF3IP2-induced lymphoma-bearing mice (bottom) and nine 
representative mice that were lymphoma-free at the end of follow up (top). b, Representative lymph nodes 
from FYN-TRAF3IP2-induced lymphoma-bearing mice. c, Representative FACS plots showing GFP+ CD4+ 
FYN-TRAF3IP2 lymphoma cells infiltrating lymph nodes and bone marrow. d, Representative histological 
micrographs of H&E stained liver, lung, and kidney of Tet2fl/fl or Tet2-/- FYN-TRAF3IP2-induced lymphoma-
bearing animals and the GFP only control. e, Representative FACS plots of mononuclear cells collected from 




Figure 4.4 – FYN-TRAF3IP2-induced mouse lymphoma T cells show limited TFH features. a, Gating 
strategy for CD4+ GFP- non-tumor cell and CD4+ GFP+ tumor cell population. b, Flow cytometry analysis of 
PD1 and CXCR5 TFH cell marker expression in CD4+ GFP- non-tumor cells and CD4+ GFP+ tumor cells from 
a representative FYN-TRAF3IP2-induced lymphoma-bearing spleen. c, Representative flow cytometry 
analyses of PD1, ICOS and BCL6 TFH cell marker expression in CD4+ GFP+ spleen tumor cells compared to 
CD4+ GFP- non-tumor cells from the same spleen. d, Heatmap representation of TFH-associated marker 
expression in CD4+ naïve wild type T cells, FYN-TRAF3IP2-induced CD4+ GFP+ lymphoma cells and RHOA 
G17V AITL-like mouse tumor cells (Cortes et al. 2018). e, GSEA enrichment plots of differentially expressed 
genes associated with FYN-TRAF3IP2-induced mouse lymphoma cells compared to wild type naïve CD4+ T 
cells. AITL geneset: top differentially upregulated genes in AITL compared with PTCL, NOS (fold change 1.5, 








Figure 4.5 – FYN-TRAF3IP2-induced mouse PTCL, NOS are transplantable. a, Kaplan-Meier survival 
curve of mice transplanted with cell suspension containing FYN-TRAF3IP2 GFP+ lymphoma infiltrate. b, 
Spleens of secondary recipients transplanted with FYN-TRAF3IP2-induced lymphoma infiltrate. c, 
Representative histological micrographs of H&E stained spleen, liver, and lung of lymphoma transplanted 
mice at the endpoint showing lymphoma infiltration. Scale bar = 400 μm. d, Representative FACS plot showing 
GFP+ CD4+ lymphoma infiltrates in spleens from diseased secondary recipients. e, Representative flow 
cytometry analyses of PD1, ICOS and BCL6 TFH cell marker expression in CD4+ GFP+ spleen tumor cells 
compared to CD4+ GFP- non-tumor cells from the same spleen. f, Pie chart representation of Tcrb gene clonal 
analysis of three secondary Tet2-/- FYN-TRAF3IP2 GFP+ lymphomas (top) and side-by-side representation of 
Tcrb sequence reads from primary and secondary Tet2-/- FYN-TRAF3IP2 GFP+ lymphomas (bottom), 





Chapter 5: NF-κB activation as driver and therapeutic target in 
FYN-TRAF3IP2-induced PTCL 
 
In agreement with a role of FYN-TRAF3IP2 as driver of NF-κB activation, examination of nuclear 
RelA/p65 NF-κB subunit in FYN-TRAF3IP2 CD4+ GFP+ mouse lymphoma cells showed clear 
nuclear localization pattern of NF-κB transcription factor by immunofluorescence analysis (Figure 
5.1a,b)  and significantly increased levels of active phosphorylated p65 proteins by flow cytometry 
analysis (Figure 5.1c). Transcriptomic profiling of FYN-TRAF3IP2 lymphoma tumor lymphocytes 
by RNAseq compared with normal CD4+ T cells (Figure 5.2a-c) revealed marked enrichment of 
gene sets indicative of NF-κB activation, including NF-κB transcriptional targets and constitutive 
canonical NF-κB activation in lymphoma (Saba et al. 2016) (Figure 5.1d-f). Finally, and 
consistently with immunophenotypic analyses, FYN-TRAF3IP2 CD4+ GFP+ lymphoma cells 
showed upregulation of Pdcd1 and Icos, but not of other TFH/AITL-associated genes including 
Bcl6, Maf, Irf4, Cxcl13 and Cxcr5 (Figure 4.4d). Similarly, GSEA analyses revealed no significant 
enrichment of TFH (Chtanova et al. 2004) and AITL (de Leval et al. 2007)-associated gene 
signatures in FYN-TRAF3IP2 CD4+ GFP+ tumor cells (Figure 4.4e). In all, these analyses support 
an oncogenic role for FYN-TRAF3IP2 in the development of PTCL, NOS tumors in mice. 
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Figure 5.1 – NF-κB activation in FYN-TRAF3IP2-induced mouse PTCL, NOS. a, Immunofluorescence 
analysis of p65 NF-κB intracellular localization in normal CD4+ cells from mice transplanted with GFP+ 
expressing retroviruses, in GFP+ Tet2-/- FYN-TRAF3IP2 CD4+ lymphoma cells and in isogenic wild type CD4+ 
naïve T cells.  p65 proteins shown in red and DAPI-stained nuclei in blue. Scale bar = 5 μm. b, Quantitation 
(n=20 cells per group) of p65 NF-κB intracellular nuclear/cytoplasmic localization in CD4+ cells as in a. N/C 
ratio, nuclear / cytoplasmic ratio. Boxplot shows lines represent median, boxes represent 25–75% intervals, 
whiskers represent 10–90% intervals and circles represent data points outside the 10–90% interval. P values 
were calculated using two-tailed Student’s t-test. c, Flow cytometry analysis of phospho-p65 NF-κB 
transcription factor levels in FYN-TRAF3IP2-induced CD4+ GFP+ lymphoma cells compared to wild type CD4+ 
T cell controls. Horizontal lines in the graph indicate the mean, and circles represent values for six independent 
tumors (two Tet2fl/fl FYN-TRAF3IP2 and four Tet2-/- FYN-TRAF3IP2 lymphomas) and three normal CD4+ T 
cell control samples. The P value was calculated using two-tailed Student’s t-test. AF647, Alexa Fluor 647. d, 
Bar graph representation of enrichment scores for NF-κB gene signatures obtained by Gene Set Enrichment 
Analysis (GSEA) of differentially expressed genes associated with FYN-TRAF3IP2-induced mouse CD4+ 
PTCL, NOS. BCL, B cell lymphoma. e, GSEA plot cprresponding to analysis of the NF-κB target geneset of 
the BU Gilmore lab database as in d. f, Heat map representation of differential gene expression for GSEA 
leading edge genes as in e. Scale bar shows color-coded differential expression, with red indicating higher 
levels of expression and blue indicating lower levels of expression. 
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Figure 5.2 – Transcriptomic profiling of FYN-TRAF3IP2 mouse PTCL, NOS by RNAseq. a-c, RNAseq 
data of six independent FYN-TRAF3IP2-induced mouse CD4+ GFP+ lymphomas and wild type isogenic mouse 
naïve CD4+ T cells: a, heat map of the top 100 differentially expressed genes between FYN-TRAF3IP2-
induced tumors and wild type CD4+ naïve T cells (mouse genes without known human orthologues excluded; 
scale bar shows color-coded differential expression, with red indicating higher levels of expression and blue 
indicating lower levels of expression); b, Volcano plot of all differentially expressed genes as in a (P value 
<0.001 and |log2(fold change)|> 1 deemed significant). Blue, significantly downregulated genes. Red, 
significantly upregulated genes. The number of significantly downregulated or upregulated genes is indicated; 
c, Principal component analysis plot of RNAseq data as in a. d-e, GSEA analyses of differentially expressed 
genes associated with FYN-TRAF3IP2-induced mouse lymphomas based on the RNAseq data and the 
Hallmark signatures (Liberzon et al. 2015) from MSigDB. The top 6 upregulated signatures d and top 6 
downregulated signatures e are represented as bar graphs of normalized enrichment scores and P values. 
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Activation of NF-κB by FYN-TRAF3IP2 in cell reporter assays and a prominent NF-κB-associated 
gene signature in FYN-TRAF3IP2-induced lymphomas support a driver role and potential 
therapeutic target for NF-κB signaling in PTCL. To test this hypothesis, we evaluated the 
therapeutic activity of IKK inhibitors, which block NF-κB signaling downstream of TRAF6 activation 
(Awasthee et al. 2019). In vitro treatment of FYN-TRAF3IP2 mouse tumor cells with the IKK 
inhibitors BMS-345541 (Burke et al. 2003) and IKK-16 (Waelchli et al. 2006) induced strong dose-
dependent anti-lymphoma effects (Figure 5.3a) with G1 cell cycle arrest (Figure 5.3c) and 
increased apoptosis (Figure 5.3b). To further test the antitumor activity of IKK inhibition in vivo we 
treated mice bearing luciferized FYN-TRAF3IP2 mouse tumors with BMS-345541, an allosteric 
IKK2 inhibitor with verified activity in vivo (Burke et al. 2003)  and monitored therapeutic response 
by in vivo bioimaging. In these experiments, IKK inhibitor treatment of FYN-TRAF3IP2 lymphomas 
resulted in marked anti-tumor effects (Figure 5.3e) with prolonged survival (Figure 5.3f) and 
reduced splenic tumor burden at the end of follow up (Figure 5.3g,h).  Mechanistically, treatment 
of FYN-TRAF3IP2 tumors with BMS-345541 induced suppression of NF-κB activation in vivo as 
evidenced by loss of RelA/p65 nuclear localization (Figure 5.3d), along with decreased lymphoma 
cell proliferation and increased apoptosis as determined by immunohistochemical analyses of Ki67 
and cleaved caspase 3, respectively (Figure 5.3i).  These results support a driver mechanistic role 
for NF-κB signaling in FYN-TRAF3IP2 tumor cell proliferation and survival and as therapeutic target 
for the treatment of PTCL. 
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Figure 5.3 – Anti-lymphoma effects of NF-κB inhibition in FYN-TRAF3IP2-induced PTCL tumors. a, In 
vitro dose response analysis of FYN-TRAF3IP2-induced mouse lymphoma cells to IKK beta inhibitors, BMS-
345541 and IKK-16. b, Representative FACS plots and quantitation of apoptosis in FYN-TRAF3IP2-induced 
mouse lymphoma cells treated in vitro with DMSO and IC50 concentration of BMS-345541 (5 μM) and IKK-
16 (2 μM). c, Flow cytometry analysis of cell cycle as in b. d, Immunofluorescence analysis and quantitation 
(n=20 cells per group) of p65 NF-κB nuclear/cytoplasmic localization in FYN-TRAF3IP2-induced mouse 
lymphoma cells after treatment with vehicle or BMS-345541 in vivo. P65 protein is shown in red and DAPI-
stained nuclei in blue. Scale bar = 5 μm; N/C ratio, nuclear / cytoplasmic ratio. The boxplot lines indicate the 
median, boxes represent 25–75% intervals, whiskers represent 10–90% intervals and circles represent data 
points outside the 10–90% intervals. e, Luciferase in vivo bioimaging analysis of response of FYN-TRAF3IP2-
induced mouse lymphomas treated with vehicle or BMS-345541 (n=10 mice in the vehicle group and n=9 mice 
in the treatment group). Graph indicates fold changes in bioluminescence relative to the basal signal before 
treatment. f, Kaplan-Meier survival curve of the mice treated with BMS-345541 or vehicle as in e. g, Spleen 
weight of FYN-TRAF3IP2-induced lymphoma-bearing mice treated with vehicle only or BMS-345541 at the 
endpoint as in e, f. h, Splenic tumor burden as in g. i, Immunohistochemistry analysis of cell proliferation 
(Ki67) and apoptosis (cleaved caspase-3) in spleen sections of FYN-TRAF3IP2-induced lymphoma-bearing 
mice after treatment with vehicle only or BMS-345541. Scale bar = 100 μm. Horizontal lines in graphs shown 
in e, g, and h indicate mean and circles correspond to individual values. P values in b, c, d, e, g and h were 




The clinical and biological heterogeneity of PTCLs has been a major challenge in developing an 
effective treatment strategy for the disease. While advances in genomic sequencing technologies 
have facilitated the detection of recurrent genetic alterations in each PTCL subtype, the rarity of 
the most identified mutations has hindered the development of targeted therapy and improvement 
in clinical outcomes. 
AITL and PTCL, NOS are the two most common subtypes of PTCL, together accounting for almost 
half of all cases. As discussed in chapter 1, exome sequencing studies in AITL and PTCL, NOS 
have revealed an overlapping set of point mutations, indels, and copy number changes in genes 
involved in epigenetic regulation and T-cell receptor (TCR) signaling. However, few oncogenic 
driver mutations identified so far are prevalent and targetable to promise clinical success, and the 
survival rates of AITL and PTCL, NOS remain to be about 30% at 5 years.  
Identification and characterization of chromosomal rearrangements have contributed significantly 
to the understanding and clinical management of other neoplasms, perhaps most famously in 
hematologic malignancies (Das and Tan 2013, Wang et al. 2017). In AITL and PTCL, NOS, 
however, few have reported recurrent oncogenic gene fusions with the exception of the rare ITK-
SYK and VAV1 chimeric oncogenes. 
In chapter 2, this study reports a novel fusion oncogene FYN-TRAF3IP2 that is present in about 
40% of AITL and PTCL, NOS. As described in chapter 3, FYN-TRAF3IP2 aberrantly activates NF-
κB signaling in response to TCR stimulation or to the treatment with the diacylglycerol analog, and 
independently of CBM signalosome, a multiprotein complex that translates the proximal TCR signal 
into NF-κB activation effector pathway. The physiologic role of TRAF3IP2 protein and the necessity 
of the ubiquitin ligase TRAF6 in the signal transduction strongly indicate the canonical pathway 
activation in FYN-TRAF3IP2 signaling. While elucidating the exact mechanism requires further 
study, FYN-TRAF3IP2 most likely initiates NF-κB signaling by forming a poly-ubiquitinated 
signalosome, to which (1) binding partners of FYN SH3 and SH2 domains, (2) FYN SH4-mediated 
membrane localization and CD3 interaction, and resultant proximity to other TCR activation 
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downstream complexes, (3) inherent ubiquitin ligase activity of TRAF3IP2, and (4) trans-auto-
binding of TRAF3IP2 moiety by homotypic SEFIR interaction may all contribute. In addition, it may 
be illuminating to explore the role of diacylglycerol analog in FYN-TRAF3IP2 signaling. 
Diacylglycerol is a second messenger that binds to and activates protein kinase C (PKC) isozymes 
and other C1 domain-containing proteins, such as protein kinase D (PKD) isozymes, Ras guanyl 
nucleotide-releasing proteins (RasGRPs), chimaerins, diacylglycerol kinases (DGKs), and Munc13 
proteins (Griner and Kazanietz 2007). Is it PKC, a classic target of diacylglycerol-mediated 
activation, or another C1 domain-containing enzyme that activates and amplifies FYN-TRAF3IP2 
signaling in T cells? Are any of them binding partners and activators of the FYN-TRAF3IP2 protein? 
As described in chapter 4, expression of FYN-TRAF3IP2 in murine hematopoietic progenitors 
induces NF-κB activated CD4+ mature T-cell lymphoma in vivo that recapitulates the characteristics 
of human PTCL, NOS. The CD4+ immunophenotype of all FYN-TRAF3IP2-induced lymphomas 
suggests T-cell specific nature of the fusion oncogene and coincide with the mechanistic data 
indicative of the FYN-TRAF3IP2 function in translating TCR signal to aberrant NF-κB activity. 
In fact, chapter 5 describes NF-κB activation in FYN-TRAF3IP2-induced mouse PTCL, NOS, 
evidenced by p65 nuclear localization, increased phospho-p65 levels, and enrichment of NF-κB 
signature in transcriptomic profiling. Moreover, NF-κB inhibition by IKK inhibitors exerts significant 
anti-lymphoma effect on FYN-TRAF3IP2-induced mouse PTCL, NOS, highlighting the driving role 
of NF-κB activation in FYN-TRAF3IP2-mediated T-cell transformation. 
Previous studies have provided evidence of NF-κB activation in AITL and PTCL, NOS as discussed 
in chapter 1: sequencing studies in AITL and PTCL, NOS have reported mutations in a diverse set 
of genes involved in NF-κB activation; a large-scale gene expression profiling study across PTCL 
subtypes in human implicated NF-κB signaling in AITL and some PTCL, NOS; and all published 
AITL and PTCL, NOS mouse models document NF-κB activation in the tumors. 
Taken together, FYN-TRAF3IP2 induces T cell transformation by aberrantly activating NF-κB, 
which may be the shared oncogenic mechanism of AITL and a subset of PTCL, NOS. 
This interpretation is also consistent with the overrepresentation of AITL and PTCL, NOS in the 
FYN-TRAF3IP2 distribution pattern across PTCL subtypes. Of note, while it expresses some TFH 
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markers that are also NF-κB target genes, FYN-TRAF3IP2-induced mouse PTCL, NOS does not 
seem to have originated from TFH. 
Therapeutically, marked improvement in survival and tumor burden in response to IKK inhibitor 
BMS-345541 in FYN-TRAFIP2 lymphoma-bearing mice suggests NF-κB inhibition as a strong 
candidate for targeted clinical intervention in PTCL. As reviewed in chapter 1, constitutive NF-κB 
activation drives oncogenesis in several other lymphoid neoplasms by promoting survival and 
proliferation of tumor cells and by supporting the microenvironment via angiogenesis and 
inflammation. Drawing comparison, transcriptomic profiling of FYN-TRAF3IP2-induced mouse 
PTCL shows strong enrichment in NF-κB target genes involved in anti-apoptosis and inflammation. 
Relatedly, the strong response to NF-κB inhibition in these mouse tumors may stem from the 
inhibitor’s action against both the tumor cells and the microenvironment components that support 
lymphoma progression. Given that the microenvironmental components are a major fraction of the 
disease infiltrate, the supposed dual function of the NF-κB inhibition may be particularly effective 
in PTCL. Interestingly, recent phase Ib/IIa trial tested the combination of proteaseome inhibitor 
carfilzomib, immunomodulatory drug lenalidomide, and HDAC inhibitor romidepsin in PTCL and 
showed promising results in patients with relapsed and refractory AITL (CR in 4/5 patients) (Mehta-
Shah et al. 2016). The combination resembles the multiple myeloma treatment strategy which 
suppresses tumorigenic NF-κB activation by combining proteasome inhibitor and 
immunomodulatory drug in addition to steroid. 
In conclusion, this study highlights the role of NF-κB signaling as a driver of T-cell transformation 




Materials and Methods 
Patient samples 
Tumor banks at the Columbia University Medical Center (New York, New York, USA) and Cornell 
University Medical Center (New York, NY, USA) provided DNA and RNA samples from PTCL 
biopsies. Samples were obtained with informed consent, and analysis was conducted under the 
supervision of the Columbia University Medical Center Institutional Review Board.  
FYN-TRAF3IP2 gene fusion detection and validation 
We analyzed a panel of 101 RNAseq PTCL samples generated by Illumina HiSeq paired-end 
sequencing as previously described (Abate et al. 2017). To detect gene fusions in the data we used 
the ChimeraScan algorithm (Iyer et al. 2011), which identifies gene fusion candidates by detecting 
read pairs discordantly mapping to two different genes. From this analysis, we then successively 
reduced the candidate list by applying homology-based filters and by detecting reads spanning 
junction breakpoints (split reads). To further improve our search for driver oncogenic fusions, we 
applied the Pegasus pipeline (Abate et al. 2014). Briefly, Pegasus reconstructs the entire fusion 
sequence and annotates lost and preserved protein domains in the gene partners. Next, the 
algorithm applies a pre-trained classification model to the candidate fusion to derive a probability 
of it being an oncogenic driver event (termed the Pegasus driver score). In-frame gene fusions with 
a Pegasus driver score greater than 0.5 were selected for further experimental validation. 
To investigate the presence of the FYN-TRAF3IP2 fusion mRNAs in each of the index samples 
and in the additional independent panel of 28 samples, we synthesized cDNA from patient total 
RNA isolated from frozen PTCL biopsies using oligo(dT)20 primers and the SuperScript™ IV First-
Strand Synthesis System (Invitrogen #18091050) following manufacturer’s protocol. We then PCR 
amplified the region flanking the fusion breakpoint using KAPA HiFi HotStart ReadyMix PCR Kit 
(Kapa Biosystems #KK2601) and the following primers: FYN_466-488_FWD 
GAAAAGATGCTGAGCGACAGC and TRAF3IP2_91-70_REV CCTCTTCCGGGGAATATTCTGG 
and validated the fusion transcript by dideoxynucleotide sequencing (GENEWIZ, South Plainfield, 
NJ). 
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We analyzed the genomic DNA extracted from the patient lymphoma biopsy harboring FYN-
TRAF3IP2 fusion mRNA after deep (100x) whole genome sequencing performed by GENEWIZ on 
Illumina HiSeq platform following the DNA library preparation using NEBNext® Ultra™ DNA Library 
Prep Kit. Briefly, acoustic shearing with a Covaris LE220 instrument fragmented the genomic DNA, 
which was then end repaired, adenylated and ligated with adapters at the 3’ ends. Enrichment of 
the ligated fragments by limited cycle PCR generated the DNA library, which was validated using 
D1000 ScreenTape on the Agilent 4200 TapeStation (Agilent Technologies, Palo Alto, CA, USA) 
and was quantified using Qubit 2.0 Fluorometer and by real time PCR (Applied Biosystems, 
Carlsbad, CA, USA). DNA sequencing was performed on the Illumina HiSeq platform in a 2x 150 
paired-end (PE) configuration using the HiSeq Control Software (HCS) on the HiSeq instrument for 
image analysis and base calling. Raw sequencing data (.bcl files) generated from Illumina HiSeq 
was converted into fastq files and de-multiplexed using Illumina's bcl2fastq software. One mismatch 
was allowed for index sequence identification. 
We identified structural variants (SV) from the whole genome sequencing data using LUMPY (Layer 
et al. 2014), which integrates multiple alignment signals, including read depth, splitter and 
discordant reads. 
Cell line and culture 
We cultured the Jurkat T cell line (American Type Culture Collection, ATCC), NF-κB/Jurkat/GFP 
transcriptional reporter cell line (System Biosciences), and CARD11-null Jurkat JPM50.6 cell line 
(Wang et al. 2002) (kindly provided by Dr. Andrew Snow, Uniformed Services University, Bethesda, 
MD) in RPMI-1640 containing 10% FBS, 100 U/mL penicillin G, and 100 µg/mL streptomycin. We 
cultured the HEK293T and HeLa cell lines (ATCC) in DMEM supplemented with 10% FBS, 100 
U/mL penicillin G, and 100 µg/mL streptomycin. We cultured the FYN-TRAF3IP2-induced murine 
PTCL cells in RPMI-1640 supplemented with 20% FBS, 100 U/mL penicillin G, 100 µg/mL 
streptomycin, 100 μM 2-mercaptoethanol and 10ng/mL IL2 (Peprotech #200-02). 
We maintained all cell cultures at 37˚C in a humidified atmosphere under 5% CO2 and regularly 
tested them for mycoplasma contamination. 
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Drugs 
We purchased IL17A (#200-17) and TNFα (#300-01A) from Peprotech, phorbol 12-myristate 13-
acetate (PMA; #P1585) and tamoxifen (#T5648) from Sigma-Aldrich, BMS-345541 (#S8044) and 
IKK-16 (#S2882) from Selleckchem, and XenoLight D-Luciferin (#122799) from Perkin Elmer. For 
in vitro assays we dissolved IL17 in sterile water and PMA, BMS-345541, and IKK-16 in DMSO. 
For in vivo studies we resuspended 100 mg tamoxifen in 100 μL of ethanol and added corn oil to 
reach a final concentration of 30 mg/mL. We then rotated the tamoxifen suspension for 1 hour at 
55°C and froze in aliquots at −20°C. We administered tamoxifen as a single 100 μL intraperitoneal 
injection per mouse. For intraperitoneal injections of BMS-345541, we prepared fresh 6 mg/mL 
aliquots in 2% DMSO, 30% PEG-400 immediately prior to each round of treatment. We used 2% 
DMSO 30% PEG-400 solution without drug for vehicle injection controls. For in vivo bioimaging, 
we resuspended luciferin in PBS to a final concentration of 15 mg/mL and administered it 
intraperitoneally 10 minutes before imaging (150 mg/kg). 
Plasmid and vectors 
We obtained pLX304-blast-V5 construct encoding TRAF3IP2 and CARD11 from the Broad 
Lentiviral Expression Library, pcDNA3 Flag-TRAF6 (#66929) from Addgene, and FUW-mCherry-
Puro-Luc from (Kimbrel et al. 2009). We cloned TRAF6 into pcDNA3.1 vector (Invitrogen #V79020) 
with N-terminal HA tag and mutagenized pLX304-CARD11 plasmid to switch the V5 tag into HA 
tag at the C-terminal using the QuikChange II XL Site-Directed Mutagenesis kit (Agilent #200522) 
according to the manufacturer’s instructions.  
We cloned the gene fusion FYN-TRAF3IP2, synthesized by GENEWIZ, and TRAF3IP2 into pLenti-
CMV-Puro vector (Addgene #17452) for human cell line lentiviral infection experiments, pMSCV 
Puro IRES GFP vector (Addgene #18751) for mouse primary cell retroviral infection experiments, 
and pcDNA3.1 vector (Invitrogen #V79020) for transient transfection experiments, with N-terminal 
Kozak sequence GCCACCATG and C-terminal V5 or 3xFLAG tag. We generated the ASVQSKDK 
and PVAVAA mutants of FYN-TRAF3IP2 by site directed mutagenesis as described above. 
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Virus production and infection 
To generate infectious viral particles, we transfected HEK293T cells with lentiviral constructs, 
pCMV ΔR8.91 and pMD.G VSVG or with retroviral constructs and pMCV-copac packaging vector 
using JetPEI transfection reagent (Polyplus #101-01), according to the manufacturer’s protocol. 
To transduce Jurkat, NF-κB/Jurkat/GFP, and JPM50.6 cell lines, we collected the lentiviral 
supernatants 48 hours after transfection and infected the cells by spinoculation. After infection, we 
selected cells for 1 week in medium containing 1 µg/mL puromycin or 2 weeks in medium containing 
1 µg/mL blasticidin. To transduce mouse primary cells, we harvested viral supernatants at 48 hours 
and 72 hours after transfection and infected the cells by spinoculation on two consecutive days. 
NF-κB reporter assays 
To analyze NF-κB activity in Jurkat cell line, we measured the median GFP intensity of NF-
κB/Jurkat/GFP cells transduced with empty vector or stably expressing wild type TRAF3IP2, fusion 
FYN-TRAF3IP2, or mutant constructs by flow cytometry under basal conditions, 12 hours after 
stimulation with 200 ng/mL IL17, 12 hours after stimulation with antibodies against human CD3, or 
6 hours after stimulation with phorbol 12-myristate 13-acetate (PMA) as indicated. To stimulate the 
cells with a-hCD3 antibodies, we incubated the ice-chilled cells with 0.5 µg/mL anti-hCD3 
antibodies (BD Biosciences #555329) on ice for 15 minutes, washed the cells with ice-cold PBS, 
and resuspended the cell pellet after centrifugation in 37°C warm complete culture media with 10 
µg/mL goat anti-mouse Ig (BD biosciences #553998) to 10 x 106 cells/mL. After 15 minutes of 
stimulation in Ig-containing media, we diluted the cell suspension to 1 x 106 cells/mL in complete 
media and cultured the cells for 12 hours before analysis. 
We similarly analyzed NF-κB reporter activity in JPM50.6 (CARD11 knockout, NF-κB-GFP reporter-
expressing Jurkat (Wang et al. 2002)) cells by measuring median GFP intensity using flow 
cytometry under basal conditions or 6 hours after stimulation with 25 nM PMA or 20 ng/mL TNFα. 
We acquired flow cytometry data using a FACS Canto cytometer (BD Biosciences) and analyzed 
it using FlowJo software (TreeStar). The results represented in the figures are representative 
technical triplicates of at least three independent experiments. 
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To analyze NF-κB activity by transient transfection followed by dual luciferase reporter assay, we 
transfected HEK293T cells with 200 ng inducible NF-kB firefly luciferase reporter plasmid (Promega 
#E8491) and 50 ng constitutively expressed Renilla luciferase plasmid (Promega #E2231) together 
with 1 ng of empty pcDNA3.1 vector or pcDNA3.1 constructs encoding wild type TRAF3IP2, fusion 
FYN-TRAF3IP2, or mutant ASVQSKDK FYN-TRAF3IP2. We measured luciferase 24 hours after 
transfection in 96-well format using Dual-Luciferase Reporter Assay Kit (Promega #E1960) and 
Microplate Reader (Promega #9300-062) according to the manufacturer’s protocols.  
Cell fractionation 
To generate whole cell lysate, we washed cells in PBS, lysed them for 30 minutes in RIPA buffer 
(50mM Tris, pH 7.5, 150mM NaCl, 1% NP-40, and 0.1% sodium deoxycholate) and centrifuged the 
samples for 10 minutes at 15,000 x g, 4°C to clear the lysate. 
For cytosolic and membrane protein extractions, we used Mem-PER™ Plus Membrane Protein 
Extraction Kit (Thermo Scientific #89842). Briefly, we extracted cytosolic proteins by resuspending 
the cell pellet in Cell Permeabilization Buffer and collecting the supernatant after centrifuging at 
400 x g, 4°C. To recover the membrane proteins from the pellet, we thoroughly washed the pellet 
in PBS, resuspended it in plasma membrane lysis buffer (50 mM Tris pH7.5. 150 mM NaCl, 1% 
NP40), incubated the sample at 4°C with shaking overnight, and collected the supernatant after 
centrifuging at 16,000 x g for 15 minutes at 4°C. 
We supplemented all extraction and wash buffers with by cOmplete™ protease inhibitor cocktail 
(Sigma Aldrich #4693159001) and PhosSTOP™ phosphatase inhibitor cocktail (Sigma Aldrich 
#4906837001) and kept them ice-cold before use. 
Immunoblot analysis 
We separated the protein extract by SDS-PAGE and transferred to nitrocellulose membranes using 
standard procedures. We detected the immunoblots using following primary antibodies against: V5 
(dilution 1:2,000) (Cell Signaling Technology #13202), GAPDH (dilution 1:10,000) (Cell Signaling 
Technology #5174), FLAG (dilution 1:1,000) (Sigma Aldrich #F1804), HSP90 (dilution 1:1,000) 
(Cell Signaling Technology #4874), Na/K ATPase (dilution 1:1,000) (Cell Signaling Technology 
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#3010), CARD11 (dilution 1:1,000) (Cell Signaling Technology #4440), HA (dilution 1:1,000) 
(Roche #11867423001), α-Tubulin (dilution 1:5,000) (Sigma Aldrich #T9026). We visualized the 
immunoblots using IRDye Secondary Antibodies (LI-COR biosciences) and Odyssey Infrared 
Imaging System (LI-COR Biosciences). We performed quantification analysis of the immunoblots 
using Image Studio software (LI-COR biosciences). 
Immunofluorescence 
To analyze the cellular localization of the TRAF3IP2 proteins, we cultured HeLa cells on the Poly-
D-Lysine-coated 12 mm glass coverslips (Corning™ #354086) and transfected them with 
pcDNA3.1 construct encoding TRAF3IP2, FYN-TRAF3IP2, or FYN-TRAF3IP2 ASVQSKDK tagged 
with 3xFLAG at the C-terminal. 48 hours after the transfection, we fixed the cells on the coverslip 
with 4% paraformaldehyde in PBS (Electron Microscopy Sciences #15700) for 20 min at room 
temperature and permeabilized and blocked them in saponin blocking buffer (3% BSA, 0.1% 
saponin in PBS) for 2 hours at room temperature. To detect the proteins, we incubated the 
coverslips overnight at 4°C in primary antibodies against FLAG (dilution 1:500) (Sigma Aldrich 
#F1804) and Na/K ATPase (dilution 1:500) (Abcam #ab76020) diluted in saponin blocking buffer. 
After washing the coverslip in 0.1% saponin in PBS, we stained the samples at room temperature 
for 1 hour in dark using fluorescently-labeled secondary antibodies: Alexa Fluor 488 against rabbit 
(dilution 1:500) (Invitrogen #A21206) and Alexa Fluor 568 against mouse (dilution 1:500) (Abcam 
#ab175700). We then washed the coverslips in PBS and mounted them in Prolong Diamond 
mounting media with DAPI (Invitrogen #P36966). 
For mouse cells, we sorted the CD4+ or CD4+ GFP+ population accordingly and resuspended the 
cell pellet in 3% paraformaldehyde, 2% sucrose in PBS to fix. We attached the fixed cells on the 
coverslips by layering the cell suspension over the Poly-D-Lysine-coated coverslips and 
centrifuging at room temperature for 10 minutes at 1200 rpm. We then washed the coverslips in 
PBS and permeabilized the cells in 0.25% TritonX-100 in PBS at room temperature for 10 minutes. 
After washing and blocking the coverslips in PBST (0.1% Tween-20 in PBS) and 4% BSA in PBST 
respectively, we labeled the p65 proteins overnight at 4°C using primary antibody (Cell Signaling 
Technology #8242) diluted 1:200 in 4% BSA-PBST. The following morning, we washed the 
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coverslips in PBST and stained the protein for 1 hour at room temperature in the dark using Alexa 
Fluor 647-conjugated antibody against rabbit (dilution 1:500) (Cell Signaling Technology #4414). 
After washing, we counterstained the cells with DAPI before mounting the coverslip in Prolong 
Glass mounting media (Invitrogen #P36982). Cells were imaged and scored the next morning. We 
acquired images on Nikon Ti Eclipse inverted confocal microscope using NIS-Elements software. 
We prepared the images for display and quantitated the fluorescent signals using NIH ImageJ/FIJI 
software. To quantify p65 intensity in cytosol and nucleus, we measured the integrated density over 
the nuclear and cytosolic area and subtracted each by background signal (calculated by multiplying 
mean gray value of background times area of region of interest). 
Immunoprecipitation 
We transfected HEK293T cells with pcDNA3.1-HA-TRAF6 and empty vector or pcDNA3.1 
constructs encoding wild type TRAF3IP2-V5, fusion FYN-TRAF3IP2-V5, or mutant PVAVAAA-
FYN-TRAF3IP2-V5, using JetPEI transfection reagent (Polyplus #101-01) according to the 
manufacturer’s protocol. After 24 hours, we collected the cells by scraping, washed in cold 1x PBS, 
and lysed for 30 minutes in Immunoprecipitation Lysis buffer (50 mM Tris pH7.5. 150 mM NaCl, 
1% NP40 supplemented with protease and phosphatase inhibitors). After clearing the lysate by 15 
minute 15,000 x g centrifugation at 4˚C, we incubated the protein extract overnight at 4°C with 
either EZview Red Anti-HA Affinity gel (Sigma Aldrich #E6779) or Anti-V5 Agarose Affinity Gel 
(Sigma Aldrich #A7345). We then washed the beads in the Immunoprecipitation Lysis buffer and 
eluted the immunoprecipitates from the beads by boiling in Laemmli sample buffer before analyzing 
them by SDS-PAGE and immunoblotting. 
Mice 
We maintained all animals in filter-topped cages on autoclaved food and water in specific pathogen-
free facilities at the Irving Cancer Research Center at Columbia University Medical Center campus. 
All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) 
at Columbia University Medical Center (Protocol # AAAU8468). The Tet2fl/fl mouse line was 
generously provided by Dr. Ross Levine at MSKCC (New York, NY) (Moran-Crusio et al. 2011). 
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CD4CreERT2 line (Tg(Cd4-cre/ERT2)11Gnri) mice, which expresses a tamoxifen-inducible form of 
the Cre recombinase under the control of the mouse Cd4 promoter (Aghajani et al. 2012), as well 
as Rag2 knockout mice (Rag2tm1.1Cgn/J) were purchased from Jackson Laboratories (Bar Harbor, 
ME). We bred Tet2fl/fl mice with CD4CreERT2 line to generate conditional inducible CD4 specific 
Tet2 knockout mice. Age- and sex-matched male and female mice of each genotype were used in 
experiments in which different genotypes were compared. For drug treatment and tumor transplant 
studies, age-matched female mice were randomly assigned to different treatment groups. Animal 
experiments were conducted in compliance with all relevant ethical regulations. Animals were 
euthanized upon showing symptoms of clinically overt disease (do not feed, lack of activity, 
abnormal grooming behavior, hunch back posture) or excessive weight loss (20% body weight loss 
or 10-15% over a week).  
Bone marrow transplantation 
To analyze the oncogenic activity of FYN-TRAF3IP2 in vivo in both wild type and Tet2-inactivated 
CD4 T cells, we harvested bone marrow cells from the long bones of Tet2fl/fl;CD4CreERT2 mice and 
isolated lineage negative cells using a magnetic bead-based, negative selection cell lineage 
depletion kit (Miltenyi Biotec #130-090-858) following manufacturer’s guidelines. We transduced 
the isolated lineage negative cells with retroviral particles encoded by pMSCV IRES GFP 
containing GFP only; TRAF3IP2-V5 and GFP; or FYN-TRAF3IP2-V5 and GFP. We transplanted 
1.75 x 105 GFP+ lineage negative cells via retro-orbital injection into lethally irradiated 8 to 12 week-
old isogenic C57BL/6 female mice. To induce Tet2 deletion in CD4+ T cells of mice assigned to 
Tet2-/- group, we treated mice transplanted with the Tet2fl/fl;CD4CreERT2 bone marrow progenitors 
with a single dose of tamoxifen (3 mg) at 8 weeks post-transplant, while administrating corn oil 
vehicle to the mice assigned to Tet2fl/fl group. To provide stimulatory signals to T cells and induce 
T cell proliferation, we immunized each mouse with 1×108 sheep red blood cells (SRBC) (Cocalico 
Biologicals #20-1334A) delivered by intraperitoneal injection every 4-5 weeks for 6 cycles. 
At the end of follow up, one animal from Tet2-/- TRAF3IP2-V5 group and one animal from Tet2-/- 
FYN-TRAF3IP2-V5 developed non-transplant-derived GFP- disease and were excluded from the 
spleen weight analysis. 
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Histopathology and immunohistochemistry 
Mouse tissues were dissected and fixed in 10% buffered formalin and paraffin-embedded at the 
Molecular Pathology Shared Resource of the Herbert Irving Comprehensive Cancer Center 
(HICCC) at Columbia University Medical Center. Tissue sections were subjected to hematoxylin-
eosin staining using standard procedures. Immunostaining for Ki67 and cleaved caspase-3 was 
performed at HistoWiz, Inc. (Brooklyn, NY). Slides were scanned using a Leica SCN 400 scanner 
and photomicrographs were examined with Aperio ImageScope Software (Leica Biosystems). 
Antibody staining for flow cytometry analysis 
We stained single cell suspensions following standard procedures using fluorochrome-conjugated 
antibodies against CD4 (RM4-5 or GK1.5, BD biosciences), PD1 (J43, eBiosciences) and ICOS 
(7E.17G9, Biolegend). 
For detection of CXCR5, we used purified anti-CXCR5 antibody (2G8) from BD Biosciences and 
followed a three-step staining protocol as previously described (Johnston et al. 2009). For 
intracellular detection of BCL6 and phospho-p65, we fixed and permeabilized the cells using Foxp3 
/ Transcription Factor Staining Buffer Set (eBiosciences 00-5523-00). Briefly, we FACS sorted 
CD4+ GFP+ FYN-TRAF3IP2-induced lymphoma cells, CD4+ GFP- matched non-tumor T cells of the 
lymphoma-bearing animals, or CD4+ T cells from wild type C57BL/6 animals into 1x 
Fixation/Permeabilization buffer prepared according to the manufacturer’s guidelines. We 
subsequently diluted the fixed cells in 1x permeabilization buffer as instructed by the manufacturer’s 
protocol and labeled the protein of interest. For BCL6, we used fluorochrome-conjugated antibody 
against BCL6 (K112-91) from BD Biosciences. For phospho-p65, we used phospho-p65 antibody 
(93H1) followed by Alexa Fluor 647-conjugated secondary antibody (#4414), both supplied by Cell 
Signaling Technology. 
We performed FACS sorting on SH800S cell sorter (SONY biotechnologies) using Sony Cell Sorter 
Software and acquired flow cytometry data using FACS Canto cytometer (BD Biosciences). We 
analyzed flow cytometry data using FlowJo software (TreeStar). 
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T cell receptor variable beta chain (TCR Vβ) repertoire analysis 
We utilized flow cytometry to analyze the TCR Vβ repertoire of the CD4+ GFP+ lymphoma 
population using a panel of 14 monoclonal antibodies directed against the variable (V) region of 
the TCRβ chain: TCR Vβ2 (B20.6), TCR Vβ5.1/5.2 (MR9-4), TCR Vβ6 (RR4-7), TCR Vβ7 (TR310), 
TCR Vβ8.1/8.2 (MR5-2), TCR Vβ9 (MR10-2), TCR Vβ11 (RR3-15), TCR Vβ12 (MR11-1) and TCR 
Vβ13 (MR12-4) from Biolegend; TCR Vβ3 (KJ25), TCR Vβ4 (KT4), TCR Vβ 8.3 (1B3.3), TCR 
Vβ10b (B21.5) and TCR Vβ 14 (14-2) from BD Pharmigen. We assessed the clonal expansion by 
comparing of the TCR Vβ repertoire distribution in GFP+ CD4+ cells versus non-tumorigenic GFP-
null CD4+ T cells from the same sample. 
In addition, TCR Vβ repertoire analysis of genomic DNA samples by TCR sequencing was 
performed at Adaptive Biotechnologies, (Seattle, USA) using the mouse immunoSEQ assay (Hsu 
et al. 2016). We analyzed TCR sequencing data using Adaptive Biotechnologies immunoSEQ 
analyzer proprietary software. 
DNA and RNA isolation 
We extracted genomic DNA and total RNA from FACS-sorted FYN-TRAF3IP2-induced mouse 
lymphoma cells using AllPrep DNA/RNA mini kit (Qiagen #80204). Briefly, we sorted CD4+ GFP+ 
lymphoma cells into appropriate volume of RLT plus buffer and isolated nucleic acid from the lysate 
according to the kit manufacturer’s protocol. 
We used RNeasy mini kit (Qiagen #74104) to extract total RNA in naïve CD4+ T cells, isolated from 
wild type C57BL/6 mouse spleen via magnetic bead-based negative selection cell depletion 
(Miltenyi Biotec #130-104-453). 
Tumor transplantation 
We injected cell suspensions (1×108 cells) extracted from lymphoma-containing spleen of diseased 
mice intravenously into 6 to 8 week-old female isogenic C57BL/6 wild type or Rag2 knockout 
immunodeficient mice. 
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RNAseq and gene expression profiling 
RNAseq libraries were prepared and sequenced on Illumina HiSeq platform by GENEWIZ. Briefly, 
sequencing libraries were prepared using Illumina Nextera XT library from the full-length cDNA 
synthesized and amplified by SMART-Seq v4 Ultra Low Input Kit (Clontech, Mountain View, CA). 
Individual libraries were pooled at equimolar concentrations and sequenced to an average depth 
of 30 million, 150 base pair, paired-end reads per sample on an Illumina HiSeq 4000 instrument. 
After trimming adapters from raw reads using Trim Galore (version 0.4.4), we aligned the reads  to 
GRCm38.p5 with the Gencode vM16 feature annotation using STAR (version 2.7) (Dobin et al. 
2013). We assigned the reads to Gencode vM16 features and computed raw counts at the gene-
level using featureCounts (version 1.6.4) (Liao et al. 2014). We performed differential gene 
expression analysis using DESeq2 (version 1.24.0) (Love et al. 2014) in R (version 3.6.0), filtering 
out genes with fewer than 15 total fragments mapped and fitting a negative binomial GLM after 
estimating library size factors and gene count dispersions. We used the fitted GLM to test contrasts 
with Wald statistics and determine the log2 fold change. To plot heatmaps and visualize expression 
data, we used log transformed, size factor normalized gene counts.  
Using javaGSEA and R, we performed Gene Set Enrichment Analysis (GSEA) (Subramanian et al. 
2005) with gene sets available in Molecular Signatures Database (MSigDB), Dr. Thomas Gilmore’s 
NF-κB target database (Boston University, Boston, MA) (http://www.bu.edu/nf-kb/gene-
resources/target-genes/), and a previously published NF-κB signature identified in the context of B 
cell lymphoma (Saba et al. 2016). 
In vitro cell viability and pharmacological treatment assays 
We measured cell growth and treatment responses of primary mouse tumors in vitro by 
measurement of the metabolic reduction of the tetrazolium salt MTT using the Cell Proliferation Kit 
I (Sigma Aldrich #11465007001) following the manufacturer’s instructions. We analyzed drug 
treatment responses following 72 hour incubation with increasing concentrations of BMS-345541 
or IKK-16. The dose response curves represented in the figures are representative technical 
triplicates of experiments on three independent mouse tumor samples. 
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Following 72 hour incubation with IC50 dose of the drugs, we quantified cell viability and apoptosis 
by flow cytometry with Annexin V-APC (BD Biosciences #550475) and 7-AAD markers (BD 
Biosciences #559925) and performed cell cycle analysis by flow cytometry after Propidium Iodide 
(Sigma Aldrich #P4864) DNA staining. The results represented in the figures are representative 
technical triplicates of at least three independent experiments. 
In vivo pharmacological treatments 
For experimental therapeutics studies, we used Tet2-/- FYN-TRAF3IP2 GFP+ PTCL, NOS tumor 
cells lentivirally infected with FUW-mCherry-Luc-puro to express luciferase. We transplanted 
luciferase-expressing lymphoma cells into Rag2 knockout mice via retro-orbital injection and 
monitored tumor development by in vivo luminescence bioimaging with the IVIS Spectrum In Vivo 
Imaging System (Perkin Elmer). 
For acute effect study, we administered vehicle only or BMS-345541 (first dose: 60 mg/kg; second 
dose 12 hours later: 100 mg/kg) intraperitoneally to animals presenting homogeneous tumor 
burden. We sacrificed the mice for analyses 6 hours after the last treatment. 
For longitudinal studies we randomly assigned animals presenting homogeneous tumor burden at 
day 14 post-transplant to two treatment cohorts, vehicle only or BMS-345541 (n=10 animals/group). 
One mouse in treatment group died before the treatment started. Following baseline tumor load 
quantification, we intraperitoneally injected BMS-345541 (25 mg/kg) or vehicle only to mice every 
other day for the first four weeks first and dosed them two consecutive days with one day off 
thereafter. We assessed the effect of BMS-345541 on overall tumor burden by in vivo bioimaging 
16 days after the start of the treatment schedule, before any lymphoma-caused mortality. We 
measured spleen weight and quantified spleen tumor burden at endpoint considering % of GFP+ 
cells and spleen weight. We collected and analyzed the in vivo bioimaging data using Living Image 
software (Perkin Elmer). 
Statistical Analyses 
We conducted statistical analyses using Prism software v8.0 (GraphPad Software, La Jolla, CA, 
USA) and considered statistical significance at P < 0.05. We reported results as mean ± SD 
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(standard deviation), as indicated in the figure legends unless otherwise stated, with significance 
annotated by P value calculated using student’s t-test assuming equal variance and normal 
distribution. For survival in mouse experiments, we represented the results as Kaplan-Meier curves 
and determined the significance using Log-rank test. Representative images correspond to 
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